QUALCOMM (QCOM) 10-Q 1 May 19 2019 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information Document - shares	6 Months Ended
	Mar. 31, 2019	Apr. 29, 2019
Document Information [Line Items]
Entity Registrant Name	QUALCOMM INC/DE
Entity Registrant State of Incorporation	Delaware
Entity Address	5775 Morehouse Dr.
Entity City	San Diego
Entity State	California
Entity Zip Code	92121-1714
Entity Phone Number	(858) 587-1121
Entity Employer ID	953685934
Entity Central Index Key	0000804328
Current Fiscal Year End Date	--09-29
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Common Stock, Shares Outstanding		1,215,698,926
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Mar. 31, 2019	Sep. 30, 2018
Current assets:
Cash and cash equivalents	$ 10,135	$ 11,777
Marketable securities	195	311
Accounts receivable, net	3,638	2,904
Inventories	1,725	1,693
Other current assets	631	699
Total current assets	16,324	17,384
Deferred tax assets	3,832	936
Property, plant and equipment, net	2,945	2,975
Goodwill	6,299	6,498
Other intangible assets, net	2,510	2,955
Other assets	2,113	1,970
Total assets	34,023	32,718
Current liabilities:
Trade accounts payable	1,667	1,825
Payroll and other benefits related liabilities	633	1,081
Unearned revenues	478	500
Short-term debt	998	1,005
Other current liabilities	6,741	6,978
Total current liabilities	10,517	11,389
Unearned revenues	1,330	1,620
Income taxes payable	1,849	2,312
Long-term debt	15,405	15,365
Other liabilities	1,056	1,225
Total liabilities	30,157	31,911
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 8 shares authorized; none outstanding	0	0
Common stock and paid-in capital, $0.0001 par value; 6,000 shares authorized; 1,214 and 1,219 shares issued and outstanding, respectively	384	0
Retained earnings	3,309	542
Accumulated other comprehensive income	173	265
Total stockholders’ equity	3,866	807
Total liabilities and stockholders’ equity	$ 34,023	$ 32,718

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS PARENTHETICALS - $ / shares	Mar. 31, 2019	Sep. 30, 2018
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	8,000,000	8,000,000
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	6,000,000,000	6,000,000,000
Common stock, shares issued	1,214,000,000	1,219,000,000
Common stock, shares outstanding	1,214,000,000	1,219,000,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2019	Mar. 25, 2018	Mar. 31, 2019	Mar. 25, 2018
Revenues:
Equipment and services	$ 3,753	$ 3,936	$ 7,506	$ 8,639
Licensing	1,229	1,284	2,318	2,616
Total revenues	4,982	5,220	9,824	11,255
Costs and expenses:
Cost of revenues	2,179	2,239	4,367	4,902
Research and development	1,308	1,402	2,577	2,822
Selling, general and administrative	573	869	1,100	1,641
Other	(18)	310	130	1,493
Total costs and expenses	4,042	4,820	8,174	10,858
Operating income	940	400	1,650	397
Interest expense	(162)	(179)	(317)	(350)
Investment and other income, net	28	96	33	211
Income before income taxes	806	317	1,366	258
Income tax (expense) benefit	(143)	13	365	(5,911)
Net income (loss)	$ 663	$ 330	$ 1,731	$ (5,653)
Basic earnings (loss) per share	$ 0.55	$ 0.22	$ 1.43	$ (3.82)
Diluted earnings (loss) per share	$ 0.55	$ 0.22	$ 1.42	$ (3.82)
Shares used in per share calculations:
Basic	1,213	1,482	1,213	1,479
Diluted	1,217	1,494	1,220	1,479

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2019	Mar. 25, 2018	Mar. 31, 2019	Mar. 25, 2018
Net income (loss)	$ 663	$ 330	$ 1,731	$ (5,653)
Other comprehensive (loss) income, net of income taxes:
Foreign currency translation (losses) gains	(17)	178	(41)	173
Reclassification of foreign currency translation (gains) losses included in net income (loss)	(2)	0	1	0
Reclassification of net other-than-temporary losses on available-for-sale securities included in net income (loss)	0	0	0	1
Net unrealized losses on other available-for-sale securities	(1)	(5)	(6)	(1)
Reclassification of net realized gains on available-for-sale securities included in net income (loss)	0	(8)	(1)	(9)
Net unrealized (losses) gains on derivative instruments	0	(7)	16	(6)
Reclassification of net realized (gains) losses on derivative instruments included in net income (loss)	(1)	2	(2)	3
Other losses	(8)	0	(8)	0
Total other comprehensive (loss) income	(29)	160	(41)	161
Comprehensive income (loss)	$ 634	$ 490	$ 1,690	$ (5,492)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	6 Months Ended
	Mar. 31, 2019	Mar. 25, 2018
Operating Activities:
Net income (loss)	$ 1,731	$ (5,653)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization expense	698	751
Income tax provision (less than) in excess of income tax payments	(958)	5,466
Non-cash portion of share-based compensation expense	452	470
Net gains on marketable securities and other investments	(9)	(73)
Indefinite and long-lived asset impairment charges	203	33
Impairment losses on marketable securities and other investments	69	20
Other items, net	(190)	52
Changes in assets and liabilities:
Accounts receivable, net	200	94
Inventories	(49)	243
Other assets	25	58
Trade accounts payable	(173)	(511)
Payroll, benefits and other liabilities	(727)	1,453
Unearned revenues	(122)	(125)
Net cash provided by operating activities	1,150	2,278
Investing Activities:
Capital expenditures	(322)	(411)
Purchases of debt and equity marketable securities	0	(5,758)
Proceeds from sales and maturities of debt and equity marketable securities	92	7,659
Acquisitions and other investments, net of cash acquired	(118)	(170)
Proceeds from other investments	39	159
Other items, net	48	2
Net cash (used) provided by investing activities	(261)	1,481
Financing Activities:
Proceeds from short-term debt	3,297	5,563
Repayment of short-term debt	(3,303)	(4,330)
Proceeds from issuance of common stock	177	335
Repurchases and retirements of common stock	(1,019)	(425)
Dividends paid	(1,502)	(1,689)
Payments of tax withholdings related to vesting of share-based awards	(143)	(196)
Payment of purchase consideration related to RF360 joint venture	0	(115)
Other items, net	(38)	(17)
Net cash used by financing activities	(2,531)	(874)
Effect of exchange rate changes on cash and cash equivalents	0	32
Net (decrease) increase in total cash and cash equivalents	(1,642)	2,917
Total cash and cash equivalents at beginning of period	11,777	37,029
Total cash and cash equivalents at end of period	10,135	39,946
Cash and cash equivalents	10,135	37,946
Restricted cash and restricted cash equivalents included in other assets	$ 0	$ 2,000

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Millions	Total	Common Stock and Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income [Member]
Balance at beginning of period at Sep. 24, 2017	$ 30,725	$ 274	$ 30,067	$ 384
Cumulative effect of accounting changes (Note 1)			0	0
Common stock issued under employee benefit plans and the related tax benefits		343
Repurchases and retirements of common stock		(425)	0
Share-based compensation		499
Tax withholdings related to vesting of share-based payments		(196)
Net income (loss)	(5,653)		(5,653)
Dividends			(1,719)
Other comprehensive (loss) income	(5,492)			161
Balance at end of period at Mar. 25, 2018	$ 23,735	495	22,695	545
Dividends per share announced	$ 1.14
Balance at beginning of period at Dec. 24, 2017	$ 23,872	265	23,222	385
Cumulative effect of accounting changes (Note 1)			0	0
Common stock issued under employee benefit plans and the related tax benefits		201
Repurchases and retirements of common stock		(200)	0
Share-based compensation		233
Tax withholdings related to vesting of share-based payments		(4)
Net income (loss)	330		330
Dividends			(857)
Other comprehensive (loss) income	490			160
Balance at end of period at Mar. 25, 2018	$ 23,735	495	22,695	545
Dividends per share announced	$ 0.57
Balance at beginning of period at Sep. 30, 2018	$ 807	0	542	265
Cumulative effect of accounting changes (Note 1)			3,455	(51)
Common stock issued under employee benefit plans and the related tax benefits		177
Repurchases and retirements of common stock		(136)	(883)
Share-based compensation		486
Tax withholdings related to vesting of share-based payments		(143)
Net income (loss)	1,731
Dividends			(1,536)
Other comprehensive (loss) income				(41)
Balance at end of period at Mar. 31, 2019	$ 3,866	384	3,309	173
Dividends per share announced	$ 1.24
Balance at beginning of period at Dec. 30, 2018	$ 3,617	0	3,415	202
Cumulative effect of accounting changes (Note 1)			0	0
Common stock issued under employee benefit plans and the related tax benefits		150
Repurchases and retirements of common stock		0	0
Share-based compensation		237
Tax withholdings related to vesting of share-based payments		(3)
Net income (loss)	663
Dividends			(769)
Other comprehensive (loss) income				(29)
Balance at end of period at Mar. 31, 2019	$ 3,866	$ 384	$ 3,309	$ 173
Dividends per share announced	$ 0.62

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies Update (Notes)	6 Months Ended
	Mar. 31, 2019
Basis of Presentation [Abstract]
Basis of Presentation and Significant Accounting Policies Update	Basis of Presentation and Significant Accounting Policies Update Financial Statement Preparation. These condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and the instructions to Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, the interim financial information includes all normal recurring adjustments necessary for a fair statement of the results for the interim periods. These condensed consolidated financial statements are unaudited and should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended September 30, 2018 . Operating results for interim periods are not necessarily indicative of operating results for an entire fiscal year. We operate and report using a 52-53 week fiscal year ending on the last Sunday in September. Each of the three-month and six-month periods ended March 31, 2019 and March 25, 2018 included 13 weeks and 26 weeks , respectively. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and the disclosure of contingent amounts in our condensed consolidated financial statements and the accompanying notes. Actual results could differ from those estimates. Certain prior year amounts have been reclassified to conform to the current year presentation. Revision of Prior Period Financial Statements. As previously disclosed, in connection with the preparation of our condensed consolidated financial statements for the three months ended December 30, 2018, we identified an immaterial error related to the recognition of certain royalty revenues of our QTL (Qualcomm Technology Licensing) segment in the quarterly and annual periods in fiscal 2018 and third and fourth quarters and annual period in fiscal 2017. In accordance with SAB No. 99, “Materiality,” and SAB No. 108, “Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements,” we evaluated the error and determined that the related impact was not material to our financial statements for any prior annual or interim period, but that correcting the cumulative impact of the error would be significant to our results of operations for the three months ended December 30, 2018 . Accordingly, we have revised previously reported financial information for such immaterial error, as previously disclosed in our Quarterly Report on Form 10-Q for the fiscal quarter ended December 30, 2018. A summary of revisions to certain previously reported financial information presented herein for comparative purposes is included in Note 11. We will also correct previously reported financial information for such immaterial error in our future filings, as applicable. Earnings (Loss) Per Common Share. Basic earnings (loss) per common share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding during the reporting period. Diluted earnings per share is computed by dividing net income by the combination of dilutive common share equivalents, comprised of shares issuable under our share-based compensation plans and shares subject to accelerated share repurchase agreements, if any, and the weighted-average number of common shares outstanding during the reporting period. Due to the net loss for the six months ended March 25, 2018 , all of the common share equivalents issuable under share-based compensation plans had an anti-dilutive effect and were therefore excluded from the computation of diluted loss per share. The following table provides information about the diluted earnings (loss) per share calculation (in millions): Three Months Ended Six Months Ended March 31, March 25, March 31, March 25, Dilutive common share equivalents included in diluted shares 3.8 12.2 7.0 — Shares of common stock equivalents not included because the effect would be anti-dilutive or certain performance conditions were not satisfied at the end of the period 17.2 0.1 14.4 44.9 Share-Based Compensation. Total share-based compensation expense, related to all of our share-based awards, was comprised as follows (in millions): Three Months Ended Six Months Ended March 31, March 25, March 31, March 25, Cost of revenues $ 7 $ 10 $ 16 $ 21 Research and development 157 151 315 307 Selling, general and administrative 57 61 121 142 Share-based compensation expense before income taxes 221 222 452 470 Related income tax benefit (30 ) (29 ) (79 ) (77 ) $ 191 $ 193 $ 373 $ 393 At March 31, 2019 , total unrecognized compensation expense related to nonvested restricted stock units granted prior to that date was $1.4 billion , which is expected to be recognized over a weighted-average period of 2.2 years . At March 31, 2019 , we had outstanding 30.4 million restricted stock units that contain only a service requirement and 3.1 million stock options that contain only a service requirement. Recently Adopted Accounting Pronouncements. Revenue Recognition: In May 2014, the Financial Accounting Standards Board (FASB) issued new accounting guidance related to revenue recognition (ASC 606), which outlines a comprehensive revenue recognition model and supersedes most current revenue recognition accounting guidance and requires increased disclosures. The new accounting guidance defines a five-step approach that requires a company to recognize revenue as control of goods or services transfers to a customer at an amount that reflects the expected consideration to be received in exchange for those goods or services. We adopted ASC 606 in the first quarter of fiscal 2019 using the modified retrospective transition method only to those contracts that were not completed as of October 1, 2018. We recognized the cumulative effect of initially applying the new revenue accounting guidance as an adjustment to opening retained earnings. Prior period results have not been restated and continue to be reported in accordance with the accounting guidance in effect for those periods (ASC 605). We have implemented new accounting policies, systems, processes and internal controls necessary to support the requirements of ASC 606. Adoption of this new accounting guidance most significantly impacts the timing of sales-based royalty revenues, which are the vast majority of our QTL segment’s revenues. Prior to adoption, we recognized sales-based royalties as revenues in the period in which such royalties were reported by licensees, which was after the conclusion of the quarter in which the licensees’ sales occurred and when all other revenue recognition criteria had been met. Under the new accounting guidance, we estimate and recognize sales-based royalties in the period in which the associated sales occur, subject to certain constraints on our ability to estimate such amounts, resulting in an acceleration of revenue recognition compared to the historical method. Since we do not invoice for sales-based royalties estimated and recognized in any given quarter until after the conclusion of that quarter (which is generally the following quarter when such royalties are reported by licensees), revenues recognized from sales-based royalties results in unbilled receivables (included in accounts receivable, net on the consolidated balance sheet). The adoption of ASC 606 did not otherwise have a material impact. The new accounting guidance also impacts the timing of recognizing certain customer incentives, which are recorded as a reduction to revenues in the period that the related revenues are earned. Prior to adoption, we accounted for certain customer incentive arrangements, including volume-related and other pricing rebates or cost reimbursements for marketing and other activities involving certain of our products and technologies, in part based on the maximum potential liability. Under the new accounting guidance, we estimate the amount of all customer incentives. The following table summarizes the cumulative effects of adopting the new revenue accounting guidance (substantially all of which related to the impact to QTL’s sales-based royalties) on our condensed consolidated balance sheet at October 1, 2018 (in millions): Balance as of September 30, Adjustment Opening Balance as of October 1, Assets Accounts receivable, net $ 2,904 $ 957 $ 3,861 Other current assets 699 1 700 Deferred tax assets 936 (98 ) 838 Other assets 1,970 1 1,971 Liabilities Unearned revenues, current $ 500 $ 6 $ 506 Other current liabilities 6,978 125 7,103 Unearned revenues 1,620 (110 ) 1,510 Stockholders’ equity Retained earnings $ 542 $ 840 $ 1,382 The following tables summarize the impacts of adopting the new revenue accounting guidance on our condensed consolidated balance sheet and statements of operations (in millions): As of March 31, 2019 Balance Sheet As Reported ASC 606 Adjustment ASC 605 Assets Accounts receivable, net $ 3,638 $ (851 ) $ 2,787 Other current assets 631 (9 ) 622 Deferred tax assets 3,832 45 3,877 Liabilities Unearned revenues, current $ 478 $ 304 $ 782 Other current liabilities 6,741 (366 ) 6,375 Unearned revenues 1,330 109 1,439 Stockholders’ equity Retained earnings $ 3,309 $ (861 ) $ 2,448 Three Months Ended March 31, 2019 Six Months Ended March 31, 2019 Statements of Operations As Reported ASC 606 Adjustment ASC 605 As Reported ASC 606 Adjustment ASC 605 Revenues Equipment and services $ 3,753 $ (55 ) $ 3,698 $ 7,506 $ (70 ) $ 7,436 Licensing 1,229 (8 ) 1,221 2,318 43 2,361 Investment and other income, net 28 (1 ) 27 33 1 34 Income tax (expense) benefit (143 ) 10 (133 ) 365 4 369 Net income 663 (54 ) 609 1,731 (22 ) 1,709 Adoption of the new accounting guidance had no impact to net cash provided (used) by operating, financing or investing activities on our condensed consolidated statement of cash flows for the six months ended March 31, 2019 . Financial Assets: In January 2016, the FASB issued new accounting guidance on classifying and measuring financial instruments, which requires that all equity investments, other than equity-method investments, in unconsolidated entities generally be measured at fair value through earnings in the statement of operations. Additionally, it changes the disclosure requirements for financial instruments. We adopted the new accounting guidance in the first quarter of fiscal 2019 using the modified retrospective transition method for investments in marketable securities, which have readily determinable fair values, with the cumulative effect of applying the new accounting guidance recognized as an adjustment to opening retained earnings. Upon adoption, we reclassified $50 million of unrealized gains, net of the associated tax effects, related to our investments in marketable securities from accumulated other comprehensive income to opening retained earnings. We have applied the prospective transition method for investments in non-marketable securities, which are investments in privately held companies that do not have readily determinable fair values and will recognize, through earnings, any unrealized gains that have accumulated in the period in which there is an observable transaction, if any. Hedge Instruments: In August 2017, the FASB issued new accounting guidance that expands and refines hedge accounting for both financial and non-financial risks, aligns the recognition and presentation of the effects of hedging instruments and hedged items in the financial statements, and includes targeted improvements related to the assessment of hedge effectiveness. The new accounting guidance also modifies disclosure requirements for hedging activities. We adopted the new accounting guidance in the first quarter of 2019 using the modified retrospective transition method and recorded a negligible adjustment to opening retained earnings. The new accounting guidance did not have a material impact on our condensed consolidated financial statements. Statement of Cash Flows: In August 2016, the FASB issued new accounting guidance related to the classification of certain cash receipts and cash payments in the statement of cash flows. We adopted the new accounting guidance in the first quarter of fiscal 2019 using the retrospective transition method for each period presented, which did not have a material impact on our condensed consolidated statements of cash flows. In November 2016, the FASB issued new accounting guidance that requires companies to include restricted cash and cash equivalents as a component in total cash and cash equivalents on the statement of cash flows. As a result, the consolidated statement of cash flows no longer reflects transfers between cash and cash equivalents and restricted cash and cash equivalents. We adopted the new accounting guidance in the first quarter of fiscal 2019 using the retrospective transition method, which results in certain amounts in fiscal 2018 being adjusted to conform to the new accounting guidance. This includes restricted cash and cash equivalents held during fiscal 2018 related to funds deposited as collateral for outstanding letters of credit in connection with a then proposed acquisition. Restricted cash and cash equivalents related to the outstanding letters of credit totaled $2.0 billion at the end of the fourth quarter of fiscal 2017 and second quarter of fiscal 2018. There was no impact of this change on the activity presented on the condensed consolidated statement of cash flows for the six months ended March 25, 2018. Income Taxes: In October 2016, the FASB issued new accounting guidance that changes the accounting for the income tax effects of intra-entity transfers of assets other than inventory. Under the new accounting guidance, the selling (transferring) entity is required to recognize a current tax expense or benefit upon transfer of the asset. Similarly, the purchasing (receiving) entity is required to recognize a deferred tax asset or deferred tax liability, as well as the related deferred tax benefit or expense, upon receipt of the asset. We adopted the new accounting guidance in the first quarter of fiscal 2019 using the modified retrospective transition method, with the cumulative effect of applying the new accounting guidance recognized as an adjustment to opening retained earnings of $2.6 billion , primarily as the result of establishing a deferred tax asset on the basis difference of certain intellectual property distributed from one of our foreign subsidiaries to a subsidiary in the United States in fiscal 2018 (Note 3). The ongoing impact of this accounting guidance will be dependent on the facts and circumstances of any transactions within its scope. Recent Accounting Pronouncements Not Yet Adopted. Leases: In February 2016, the FASB issued new accounting guidance related to leases that outlines a comprehensive lease accounting model and supersedes the current lease accounting guidance. The new accounting guidance requires lessees to recognize lease liabilities and corresponding right-of-use assets for all leases with lease terms of greater than 12 months. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. We will adopt the new accounting guidance in the first quarter of fiscal 2020 and expect to use the modified retrospective approach and to elect certain practical expedients, with the cumulative effect of applying the new accounting guidance recognized as an adjustment to opening retained earnings as of the effective date. We are in the process of determining the effects the adoption will have on our consolidated financial statements. Financial Assets: In June 2016, the FASB issued new accounting guidance that changes the accounting for recognizing impairments of financial assets. Under the new accounting guidance, credit losses for financial assets held at amortized cost will be estimated based on expected losses rather than the current incurred loss impairment model. The new accounting guidance also modifies the impairment model for available-for-sale debt securities. The new accounting guidance generally requires the modified retrospective transition method, with the cumulative effect of applying the new accounting guidance recognized as an adjustment to opening retained earnings in the year of adoption, except for certain financial assets where the prospective transition method is required, such as available-for-sale debt securities for which an other-than-temporary impairment has been recorded. We will adopt the new accounting guidance in the first quarter of fiscal 2021, and the impact of this new accounting guidance will largely depend on the composition and credit quality of our investment portfolio, as well as economic conditions at the time of adoption. Accounting Policy Update. Revenue Recognition: As a result of the adoption of ASC 606, we revised our revenue recognition policy beginning in fiscal 2019 as follows. We derive revenues principally from sales of integrated circuit products and licensing of our intellectual property. We also generate revenues by performing software hosting, software development and other services and from other product sales. The timing of revenue recognition and the amount of revenue actually recognized in each case depends upon a variety of factors, including the specific terms of each arrangement and the nature of our performance obligations. Revenues from sales of our products are recognized upon transfer of control to the customer, which is generally at the time of shipment. Revenues from providing services are typically recognized over time as our performance obligation is satisfied. Revenues from providing services were less than 5% of total revenues for all periods presented. We grant licenses or otherwise provide rights to use portions of our intellectual property portfolio, which, among other rights, includes certain patent rights essential to and/or useful in the manufacture and sale of certain wireless products. Licensees pay royalties based on their sales of products incorporating or using our licensed intellectual property and may also pay a fixed license fee in one or more installments. Sales-based royalties are generally based upon a percentage of the wholesale (i.e., licensee’s) selling price of complete licensed products, net of certain permissible deductions (including transportation, insurance, packing costs and other items). We broadly provide per unit royalty caps that apply to certain categories of complete wireless devices, namely smartphones, tablets and laptops, which in general, effectively provide for a maximum royalty amount per device. We estimate and recognize sales-based royalties on such licensed products in the period in which the associated sales occur, subject to certain constraints on our ability to estimate such royalties. Our estimates of sales-based royalties are based largely on an assessment of the volume of devices supplied into the market that incorporate or use our licensed intellectual property. We estimate sales-based royalties taking into consideration the mix of such sales on a licensee-by-licensee basis, as well as the licensees’ average wholesale prices of such products, and considers all information (historical, current and forecasted) that is reasonably available to us. Our licensees, however, do not report and pay royalties owed for sales in any given quarter until after the conclusion of that quarter, which is generally the following quarter. As a result of recognizing revenues in the period in which the licensees’ sales occur using estimates, adjustments to revenues are required in subsequent periods to reflect changes in estimates as new information becomes available, primarily resulting from actual amounts reported by our licensees. License agreements that require payment of license fees contain a single performance obligation that represents ongoing access to a portfolio of intellectual property over the license term since such agreements provide the licensee the right to access a portfolio of intellectual property that exists at inception of the license agreement and to updates and new intellectual property that is added to the licensed portfolio during the term of the agreement that are highly interdependent or interrelated. Since we expect to expend efforts to develop and transfer updates to our licensed portfolio on an even basis, license fees are recognized as revenues on a straight-line basis over the estimated period of benefit of the license to the licensee. We account for a contract with a customer/licensee when it is legally enforceable, the parties are committed to perform their respective obligations, the rights of the parties regarding the goods and/or services to be transferred are identified, payment terms are identified, the contract has commercial substance and collectability of substantially all of the consideration is probable. From time to time, companies initiate various strategies to attempt to renegotiate, reduce and/or eliminate their need to pay royalties to us for the use of our intellectual property. Certain licensees have disputed, underreported, underpaid, not reported and/or not paid royalties owed to us under their license agreements with us or reported to us in a manner that is not in compliance with their contractual obligations, and such licensees may continue to do so in the future. In such cases, we estimate and recognize licensing revenues only when we have a contract, as defined in ASC 606, and to the extent it is probable that a significant reversal of cumulative revenues recognized will not occur. We analyze the risk of a significant revenue reversal considering both the likelihood and magnitude of the reversal and, if necessary, constrain the amount of estimated revenues recognized in order to mitigate this risk, which may result in recognizing revenues less than amounts contractually owed to us. We measure revenues based on the amount of consideration we expect to receive in exchange for products or services. We record reductions to revenues for customer incentive arrangements, including volume-related and other pricing rebates and cost reimbursements for marketing and other activities involving certain of our products and technologies, in the period that the related revenues are earned. The charges for such arrangements are recorded as a reduction to accounts receivable, net or as other current liabilities based on whether we have the intent and contractual right of offset. Certain of these charges are considered variable consideration and are included in the transaction price primarily based on estimating the most likely amount expected to be provided to the customer/licensee. Revenues recognized from sales of our products and sales-based royalties are generally included in accounts receivable, net (including unbilled receivables) based on our unconditional right to payment for satisfied or partially satisfied performance obligations. We disaggregate our revenues by segment (Note 7) and type of product and services (as presented on our consolidated statement of operations), as we believe this best depicts how the nature, amount, timing and uncertainty of our revenues and cash flows are affected by economic factors. Substantially all of QCT’s revenues consist of equipment revenues that are recognized at a point in time, and substantially all of QTL’s revenues represent licensing revenues that are recognized over time. Revenues recognized from performance obligations satisfied (or partially satisfied) in previous periods were $398 million and $394 million for the three and six months ended March 31, 2019 , respectively, and primarily relate to certain customer incentives, QTL royalty revenues recognized related to devices sold in prior periods and revenues related to a development contract with one of our equity method investees. Unearned revenues (which are considered contract liabilities) consist primarily of license fees for intellectual property with continuing performance obligations. In the six months ended March 31, 2019 , we recognized revenues of $258 million that were recorded as unearned revenues at October 1, 2018. Remaining performance obligations, substantially all of which are included in unearned revenues, represent the aggregate amount of the transaction price of certain customer contracts yet to be recognized as revenues as of the end of the reporting period and exclude revenues related to (a) contracts that have an original expected duration of one year or less and (b) sales-based royalties (i.e., future royalty revenues) pursuant to our license agreements. Our remaining performance obligations are primarily comprised of certain customer contracts for which QTL received license fees upfront. At March 31, 2019, we had $1.8 billion of remaining performance obligations, of which $235 million , $470 million , $423 million , $416 million and $193 million was expected to be recognized as revenues for the remainder of fiscal 2019 and each of the subsequent four years from fiscal 2020 through 2023, respectively, and $77 million thereafter. Marketable Securities and Non-Marketable Securities: Prior to the adoption of the new accounting guidance in the first quarter of fiscal 2019, investments in marketable equity securities were generally classified as available-for-sale equity investments, with net unrealized gains or losses recorded as a component of accumulated other comprehensive income, net of income taxes. Beginning in fiscal 2019, all gains and losses on investments in marketable equity securities, realized and unrealized, are recognized in investment and other income, net. Prior to the adoption of the new accounting guidance in the first quarter of fiscal 2019, investments in non-marketable equity securities were recorded at cost less impairment, if any, with any losses resulting from an impairment recognized in investment and other income, net. Beginning in fiscal 2019, investments in non-marketable equity securities are recorded at cost, less impairments (if any), adjusted for observable price changes in orderly transactions for identical or similar securities (if any). All gains and losses on investments in non-marketable equity securities, realized and unrealized, are recognized in investment and other income, net.

Composition of Certain Financia

Composition of Certain Financial Statement Items (Notes)	6 Months Ended
	Mar. 31, 2019
Balance Sheet Related Disclosures [Abstract]
Composition of Certain Financial Statement Items	Composition of Certain Financial Statement Items Accounts Receivable (in millions) March 31, September 30, Trade, net of allowances for doubtful accounts of $47 and $56, respectively $ 2,430 $ 2,667 Unbilled receivables 1,196 201 Other 12 36 $ 3,638 $ 2,904 The increase in unbilled receivables was primarily due to the adoption of ASC 606 (Note 1). Accounts receivable at March 31, 2019 and September 30, 2018 included approximately $960 million related to the short payment in the second quarter of fiscal 2017 of royalties reported by and deemed collectible from Apple’s contract manufacturers. This same amount was recorded in customer-related liabilities (in other current liabilities) for Apple, since we do not have the contractual right to offset these amounts. On April 16, 2019, we entered into settlement agreements with Apple and its contract manufacturers to dismiss all outstanding litigation between the parties, and as a result, these amounts were settled (Note 12). Inventories (in millions) March 31, September 30, Raw materials $ 79 $ 72 Work-in-process 820 715 Finished goods 826 906 $ 1,725 $ 1,693 Equity Method and Non-marketable Equity Investments. The carrying values of our equity method and non-marketable equity investments are recorded in other noncurrent assets and were as follows (in millions): March 31, September 30, Equity method investments $ 354 $ 402 Non-marketable equity investments 779 650 $ 1,133 $ 1,052 In the second quarter of fiscal 2019, non-marketable debt and equity securities (non-cash consideration) with an aggregate fair value of $98 million were received related to a development contract with one of our equity method investees. Since contract revenues were no longer constrained, such amount was recognized as revenues from a previously satisfied performance obligation in the second quarter of fiscal 2019. In addition, in the second quarter of fiscal 2019, non-marketable equity securities (non-cash consideration) with a fair value of $53 million were received in connection with the sale of certain assets as part of the Cost Plan (Note 8). Other Current Liabilities (in millions) March 31, September 30, Customer incentives and other customer-related liabilities $ 3,417 $ 3,500 Accrual for EC fine (Note 6) 1,137 1,167 Income taxes payable 428 453 RF360 Holdings put and call option 1,145 1,137 Other 614 721 $ 6,741 $ 6,978 Beginning on August 4, 2019, for a period of 60 days, we have the option to acquire (and the minority owner has the option to sell) the minority ownership interest in the RF360 Holdings joint venture for $1.15 billion, and we expect one of such options to be exercised during this period. At March 31, 2019 and September 30, 2018 , the accreted value of such amount was included in other current liabilities. Accumulated Other Comprehensive Income. Changes in the components of accumulated other comprehensive income, net of income taxes, in stockholders’ equity in the six months ended March 31, 2019 were as follows (in millions): Foreign Currency Translation Adjustment Noncredit Other-than-Temporary Impairment Losses and Subsequent Changes in Fair Value for Certain Available-for-Sale Debt Securities Net Unrealized Gain (Loss) on Other Available-for-Sale Securities Net Unrealized (Loss) Gain on Derivative Instruments Other Gains Total Accumulated Other Comprehensive Income Balance at September 30, 2018 $ 11 $ 23 $ 243 $ (13 ) $ 1 $ 265 Other comprehensive (loss) income before reclassifications (41 ) — (6 ) 16 (8 ) (39 ) Reclassifications from accumulated other comprehensive income 1 — (51 ) (3 ) — (53 ) Other comprehensive (loss) income (40 ) — (57 ) 13 (8 ) (92 ) Balance at March 31, 2019 $ (29 ) $ 23 $ 186 $ — $ (7 ) $ 173 Reclassifications from accumulated other comprehensive income included adjustments of $51 million to the opening retained earnings balance as a result of the adoption of new accounting guidance in the first quarter of fiscal 2019 related to financial instruments and hedge instruments (Note 1). Reclassifications from accumulated other comprehensive income (excluding adjustments to opening retained earnings) related to available-for-sale securities were negligible in the three and six months ended March 31, 2019 and March 25, 2018 and were recorded in investment and other income, net. Other Income, Costs and Expenses. Other income in the three months ended March 31, 2019 included a $43 million gain due to the partial recovery of a fine imposed in fiscal 2009 resulting from our appeal of the Korea Fair Trade Commission (KFTC) decision (Note 6), partially offset by $25 million in net restructuring and restructuring-related charges related to our Cost Plan (Note 8). Other expenses in the six months ended March 31, 2019 included $204 million in net restructuring and restructuring-related charges related to our Cost Plan, partially offset by a $43 million gain due to the partial recovery of a fine we previously paid to the KFTC and a $31 million gain related to a favorable legal settlement. Other expenses in the three months ended March 25, 2018 consisted of $310 million in restructuring and restructuring-related charges related to our Cost Plan. Other expenses in the six months ended March 25, 2018 also included a $1.2 billion charge related to the European Commission (EC) fine (Note 6). Investment and Other Income, Net (in millions) Three Months Ended Six Months Ended March 31, March 25, March 31, March 25, Interest and dividend income $ 80 $ 154 $ 155 $ 280 Net gains (losses) on marketable securities 40 3 (33 ) 13 Net gains on other investments 6 47 42 60 Impairment losses on marketable securities and other investments (60 ) (11 ) (69 ) (20 ) Net (losses) gains on derivative investments (1 ) 10 (9 ) 9 Equity in net losses of investees (36 ) (17 ) (58 ) (38 ) Net (losses) gains on foreign currency transactions (1 ) (90 ) 5 (93 ) $ 28 $ 96 $ 33 $ 211

Income Taxes (Notes)

Income Taxes (Notes)	6 Months Ended
	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The 2017 Tax Cuts and Jobs Act (the Tax Legislation) significantly revised the United States corporate income tax by, among other things, lowering the corporate income tax rate to 21% and imposing a one-time repatriation tax on deemed repatriated earnings and profits of U.S.-owned foreign subsidiaries (the Toll Charge). The Tax Legislation fundamentally changed the taxation of multinational entities, including a shift from a system of worldwide taxation with deferral to a hybrid territorial system, featuring a participation exemption regime with current taxation of certain foreign income, a minimum tax on low-taxed foreign earnings and new measures to deter base erosion and promote U.S. production. As a fiscal-year taxpayer, certain provisions of the Tax Legislation became effective starting at the beginning of fiscal 2019, including new taxes due on certain foreign income, such as GILTI (global intangible low-taxed income), BEAT (base-erosion and anti-abuse tax) and FDII (foreign-derived intangible income). In response to the Tax Legislation, we implemented certain tax restructuring in fiscal 2018 and 2019. As a result, without considering the effects of the agreements with Apple and its contract manufacturers signed in April 2019 (Note 12) , substantially all of our income is in the U.S. and qualifies for preferential treatment as FDII, and the impact of GILTI and BEAT are negligible. Accordingly, our estimated annual effective tax rate for fiscal 2019 reflects the effects of these components of the Tax Legislation. Our annual effective tax rate for fiscal 2018 reflected a blended federal statutory rate of approximately 25% . As a result of the Tax Legislation, in fiscal 2019, several of our foreign subsidiaries made tax elections to be treated as U.S. branches for federal income tax purposes (commonly referred to as “check-the-box” elections) effective beginning in fiscal 2018 and 2019. We believe that by treating these foreign subsidiaries as U.S. branches for federal income taxes, rather than controlled foreign corporations, we will significantly reduce the risk of being subject to GILTI and BEAT taxes. As a result of making these check-the-box elections in the first quarter of fiscal 2019, we recorded a tax benefit of $570 million due to establishing new U.S. net deferred tax assets resulting from the difference between the GAAP basis and the U.S. federal tax carryover basis of the existing assets and liabilities of those foreign subsidiaries, primarily related to customer incentive liabilities that have not been deducted for tax purposes. Additionally, during fiscal 2018, one of our foreign subsidiaries distributed certain intellectual property to a U.S. subsidiary resulting in a difference between the GAAP basis and the U.S. federal tax basis of the distributed intellectual property. Upon adoption of new accounting guidance in the first quarter of fiscal 2019, we recorded a deferred tax asset of approximately $2.6 billion, primarily related to the distributed intellectual property, with an adjustment to opening retained earnings (Note 1). Our second quarter of fiscal 2019 results reflected an estimated annual effective income tax rate of approximately 6% benefit for fiscal 2019 , which included the impact of the tax benefit of $570 million (which was recorded discretely in the first quarter) due to establishing new U.S. net deferred tax assets from making certain check-the-box elections and excluded the effects of the agreements with Apple and its contract manufacturers signed in April 2019. The estimated annual effective tax rate for fiscal 2019 also reflected benefits from our FDII deduction and research and development tax credits. The annual effective tax rate for fiscal 2018 was impacted by the combined effect of the Toll Charge, the remeasurement of deferred tax assets and liabilities and our decision to no longer indefinitely reinvest certain foreign earnings, all of which resulted from the Tax Legislation. The annual effective tax rate for fiscal 2018 was also impacted by the termination fee paid to NXP Semiconductors N.V. (NXP), the EC fine, settlement with the Taiwan Fair Trade Commission (TFTC), allocation of expenses to our U.S. operations and new Singapore tax incentives. The effective tax rate of 18% for the second quarter of fiscal 2019 was higher than the estimated annual effective tax rate of 6% benefit primarily due to the tax benefit of $570 million , which was recorded discretely in the first quarter. Unrecognized tax benefits were $228 million and $217 million at March 31, 2019 and September 30, 2018 , respectively. We believe that it is reasonably possible that the total amounts of unrecognized tax benefits at March 31, 2019 may increase or decrease in the next 12 months. The United States Treasury Department has issued proposed regulations on several provisions of the Tax Legislation, including foreign tax credits, FDII, GILTI, BEAT and interest expense deduction limitations, which are expected to be finalized in the next several months. When finalized, these proposed regulations may adversely affect our provision for income taxes, results of operations and/or cash flows. We are subject to income taxes in the United States and numerous foreign jurisdictions and are currently under examination by various tax authorities worldwide, most notably in countries where we earn a routine return and tax authorities believe substantial value-add activities are performed. These examinations are at various stages with respect to assessments, claims, deficiencies and refunds, many of which are open for periods after fiscal 2000. We continually assess the likelihood and amount of potential adjustments and adjust the income tax provision, income taxes payable and deferred taxes in the period in which the facts give rise to a revision become known. As of March 31, 2019 , we believe that adequate amounts have been reserved for based on facts known. However, the final determination of tax audits and any related legal proceedings could materially differ from amounts reflected in our income tax provision and the related accruals.

Capital Stock (Notes)

Capital Stock (Notes)	6 Months Ended
	Mar. 31, 2019
Stockholders' Equity Attributable to Parent [Abstract]
Capital Stock	Capital Stock Stock Repurchase Program. On July 26, 2018 , we announced a stock repurchase program authorizing us to repurchase up to $30 billion of our common stock. The stock repurchase program has no expiration date. In September 2018 , we entered into three accelerated share repurchase agreements (ASR Agreements) with three financial institutions under which we paid an aggregate of $16.0 billion upfront and received an initial delivery of 178.4 million shares of our common stock, which were retired. The final number of shares to be repurchased will be based on the volume-weighted average stock price of our common stock during the terms of the transactions, less a discount and subject to adjustments pursuant to the terms and conditions of the ASR Agreements and will also be retired upon delivery to us. The ASR Agreements are scheduled to terminate in early September 2019 , but may terminate earlier in certain circumstances. At settlement, one or more of the financial institutions may be required to deliver additional shares of common stock to us, or under certain circumstances, we may be required to deliver shares of common stock or make a cash payment to one or more of the financial institutions, with the method of settlement at our election. In the six months ended March 31, 2019 and March 25, 2018 , we repurchased and retired 16.8 million and 6.8 million shares for $1.0 billion and $425 million , respectively, before commissions. To reflect share repurchases in the consolidated balance sheet, we (i) reduce common stock for the par value of the shares, (ii) reduce paid-in capital for the amount in excess of par to zero during the quarter in which the shares are repurchased and (iii) record the residual amount to retained earnings, if any . At March 31, 2019 , $7.8 billion remained authorized for repurchase under our stock repurchase program.

Debt (Notes)

Debt (Notes)	6 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Debt	Debt Revolving Credit Facility. We have an Amended and Restated Revolving Credit Facility (Revolving Credit Facility) that provides for unsecured revolving facility loans, swing line loans and letters of credit in an aggregate amount of up to $5.0 billion , of which $530 million and $4.47 billion will expire in February 2020 and November 2021 , respectively. Proceeds from the Revolving Credit Facility, if drawn, are expected to be used for general corporate purposes. Loans under the Revolving Credit Facility will bear interest, at our option, at either the reserve-adjusted Eurocurrency Rate (determined in accordance with the Revolving Credit Facility) or the Base Rate (determined in accordance with the Revolving Credit Facility), in each case plus an applicable margin based on our long-term unsecured senior, non-credit enhanced debt ratings. The margins over the reserve-adjusted Eurocurrency Rate and the Base Rate will be 0.805% and 0.00% per annum, respectively. The Revolving Credit Facility has a facility fee, which accrues at a rate of 0.07% per annum. At March 31, 2019 and September 30, 2018 , we had not borrowed any funds under the Revolving Credit Facility. Commercial Paper Program. We have an unsecured commercial paper program, which provides for the issuance of up to $5.0 billion of commercial paper. Net proceeds from this program are used for general corporate purposes. Maturities of commercial paper can range from 1 day to up to 397 days . At March 31, 2019 and September 30, 2018 , we had $1.0 billion of outstanding commercial paper included in short-term debt with a weighted-average interest rate of 2.74% and 2.35% , respectively, which included fees paid to the commercial paper dealers, and weighted-average remaining days to maturity of 29 days and 16 days , respectively. The carrying value of the outstanding commercial paper approximated its estimated fair value at March 31, 2019 and September 30, 2018 . Long-term Debt. The following table provides a summary of our long-term debt (in millions, except percentages): March 31, 2019 September 30, 2018 Amount Effective Rate Amount Effective Rate May 2015 Notes Floating-rate three-month LIBOR plus 0.55% notes due May 20, 2020 $ 250 3.25% $ 250 2.93% Fixed-rate 2.25% notes due May 20, 2020 1,750 3.09% 1,750 3.13% Fixed-rate 3.00% notes due May 20, 2022 2,000 3.51% 2,000 3.73% Fixed-rate 3.45% notes due May 20, 2025 2,000 3.46% 2,000 3.46% Fixed-rate 4.65% notes due May 20, 2035 1,000 4.73% 1,000 4.73% Fixed-rate 4.80% notes due May 20, 2045 1,500 4.72% 1,500 4.72% May 2017 Notes Floating-rate three-month LIBOR plus 0.73% notes due January 30, 2023 500 3.55% 500 3.14% Fixed-rate 2.60% notes due January 30, 2023 1,500 2.70% 1,500 2.70% Fixed-rate 2.90% notes due May 20, 2024 1,500 3.01% 1,500 3.01% Fixed-rate 3.25% notes due May 20, 2027 2,000 3.46% 2,000 3.46% Fixed-rate 4.30% notes due May 20, 2047 1,500 4.47% 1,500 4.47% Total principal 15,500 15,500 Unamortized discount, including debt issuance costs (79 ) (85 ) Hedge accounting fair value adjustments (16 ) (50 ) Total long-term debt $ 15,405 $ 15,365 Reported as: Short-term debt $ — $ — Long-term debt 15,405 15,365 Total $ 15,405 $ 15,365 At March 31, 2019 and September 30, 2018 , the aggregate fair value of the notes, based on Level 2 inputs, was approximately $15.4 billion and $15.1 billion , respectively. We may redeem the outstanding fixed-rate notes at any time in whole, or from time to time in part, at specified make-whole premiums as defined in the applicable form of note. We may not redeem the outstanding floating-rate notes prior to maturity. The obligations under the notes rank equally in right of payment with all of our other senior unsecured indebtedness and will effectively rank junior to all liabilities of our subsidiaries. At March 31, 2019 , we had outstanding interest rate swaps with an aggregate notional amount of $1.8 billion related to the May 2015 Notes, which effectively converted approximately 43% and 50% of the fixed-rate notes due in 2020 and 2022, respectively, into floating-rate notes. The net gains and losses on the interest rate swaps, as well as the offsetting gains or losses on the related fixed-rate notes attributable to the hedged risks, are recorded as interest expense in the current period. We did not enter into interest rate swaps in connection with issuance of the May 2017 Notes. The effective interest rates for the notes include the interest on the notes, amortization of the discount, which includes debt issuance costs, and if applicable, adjustments related to hedging. Interest is payable in arrears quarterly for the floating-rate notes and semi-annually for the fixed-rate notes. Cash interest paid related to our commercial paper program and long-term debt, net of cash received from the related interest rate swaps, was $281 million and $317 million in the six months ended March 31, 2019 and March 25, 2018 , respectively. Debt Covenants. The Revolving Credit Facility requires that we comply with certain covenants, including one financial covenant to maintain a ratio of consolidated earnings before interest, taxes, depreciation and amortization to consolidated interest expense, as defined in each of the respective agreements, of not less than three to one at the end of each fiscal quarter . We are not subject to any financial covenants under the notes nor any covenants that would prohibit us from incurring additional indebtedness ranking equal to the notes, paying dividends, issuing securities or repurchasing securities issued by us or our subsidiaries. At March 31, 2019 and September 30, 2018 , we were in compliance with the applicable covenants under the Revolving Credit Facility.

Commitments and Contingencies (

Commitments and Contingencies (Notes)	6 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal and Regulatory Proceedings. Apple Inc. (Apple) v. QUALCOMM Incorporated: On January 20, 2017, Apple filed a complaint against us in the United States District Court for the Southern District of California seeking declarations with respect to several of our patents and alleging that we breached certain agreements and violated federal antitrust and California state unfair competition laws. In its initial complaint, Apple sought declaratory judgments of non-infringement by Apple of nine of our patents, or in the alternative, a declaration of royalties Apple must pay for the patents. Apple further sought a declaration that our sale of baseband processor chipsets exhausts our patent rights for patents embodied in those chipsets. Separately, Apple sought to enjoin us from seeking excessive royalties from Apple and to disgorge royalties paid by Apple’s contract manufacturers that the court finds were not fair, reasonable and non-discriminatory (FRAND). Apple also claimed that our refusal to make certain payments to Apple under a Business Cooperation and Patent Agreement (Cooperation Agreement) constituted a breach of contract in violation of California law and sought damages in the amount of the unpaid payments, alleged to be approximately $1 billion. In addition, Apple claimed that we have refused to deal with competitors in contravention of our agreements with applicable standard setting organizations, have used our market position to impose contractual obligations on Apple that prevented Apple from challenging our licensing practices, have tied the purchase of our CDMA-enabled and “premium” LTE-enabled chipsets to licensing certain of our patents and have required Apple to purchase baseband processor chipsets exclusively from us as a condition of our payment to Apple of certain rebates, in violation of Section 2 of the Sherman Act and the California Unfair Competition Law. Apple sought injunctive relief with respect to these claims and a judgment awarding its expenses, costs and attorneys’ fees. On April 10, 2017, we filed our Answer and Counterclaims (amended on May 24, 2017) in response to Apple’s complaint denying Apple’s claims and asserting claims against Apple. The counterclaims against Apple include tortious interference with our long-standing Subscriber Unit License Agreements (SULAs) with third-party contract manufacturers of Apple devices, causing those contract manufacturers to withhold certain royalty payments owed to us and violate their audit obligations; breach of contract and the implied covenant of good faith and fair dealing relating to the Cooperation Agreement; unjust enrichment and declaratory relief relating to the Cooperation Agreement; breach of contract based on Apple’s failure to pay amounts owed to us under a Statement of Work relating to a high-speed feature of our baseband processor chipsets; breach of the parties’ software agreement; and violation of California Unfair Competition Law based on Apple’s threatening us to prevent us from promoting the superior performance of our own baseband processor chipsets. We also seek declaratory judgments that we have satisfied our FRAND commitments with respect to Apple, and that our SULAs with the contract manufacturers do not violate either competition law or our FRAND commitments. On June 19, 2017, Apple filed a Partial Motion to Dismiss our counterclaim for violation of the California Unfair Competition Law. The court granted that motion on November 8, 2017. On June 20, 2017, Apple filed an Answer and Affirmative Defenses to the rest of our counterclaims, and also filed an Amended Complaint reiterating all of the original claims and adding claims for declaratory judgments of invalidity of the nine patents that are subject to declaratory judgment claims in the original complaint, adding new declaratory judgment claims for non-infringement, invalidity and a declaration of royalties for nine more patents. Apple also added claims for declaratory judgments that certain of our agreements are unenforceable. On July 21, 2017, we filed an Answer to Apple’s Amended Complaint as well as a motion to dismiss the new declaratory judgment claims for non-infringement, invalidity and a declaration of royalties for the nine additional patents. The court granted our motion on November 8, 2017. On May 17, 2017, we filed a complaint (captioned QUALCOMM Incorporated v. Compal Electronics, Inc. et al .) in the United States District Court for the Southern District of California against certain of Apple’s contract manufacturers, Compal Electronics, Inc. (Compal), FIH Mobile, Ltd., Hon Hai Precision Industry Co., Ltd. (together with FIH Mobile, Ltd., Foxconn), Pegatron Corporation (Pegatron) and Wistron Corporation (Wistron), asserting claims for injunctive relief, specific performance, declaratory relief and damages stemming from the defendants’ breach of contracts by ceasing the payment of royalties for iPhones and other devices which they manufacture for Apple. On July 17, 2017, Compal, Foxconn, Pegatron and Wistron each filed third-party complaints for contractual indemnity against Apple seeking to join Apple as a party to the action. On July 18, 2017, Apple filed an answer to these third-party complaints acknowledging its indemnity agreements and consenting to be joined. On that same day, the defendants filed an Answer and Counterclaims to the complaint, asserting defenses and counterclaims similar to allegations previously made by Apple in the Apple Inc. v. QUALCOMM Incorporated case discussed above. In addition, the defendants asserted certain new claims, including claims under Section 1 of the Sherman Act and California’s Cartwright Act. The defendants seek damages, declaratory relief, injunctive relief, restitution of certain royalties and other relief. Also, on July 18, 2017, Apple filed a motion to consolidate this action with the Apple Inc. v. QUALCOMM Incorporated case. On September 13, 2017, the court granted Apple’s consolidation motion. Fact discovery is closed in these cases. On August 31, 2018, Apple filed a motion for judgment on the pleadings that the court lacks subject matter jurisdiction over our counterclaim that our license offers to Apple have not violated our obligation to license standard-essential patents on FRAND terms. On March 20, 2019, the court denied Apple’s motion. Also, on August 31, 2018, Apple filed motions for partial summary judgment on the following issues: that part of our claim for Apple’s alleged tortious interference with its contract manufacturers’ agreements is barred by the statute of limitations; that our claim for damages under the Cooperation Agreement is unfounded; and that certain of our patent rights are exhausted by the sale of our baseband processor chipsets. On November 8, 2018, the court ruled on Apple’s motion regarding its alleged tortious interference, holding that Apple is not liable for tortious interference that occurred prior to January 20, 2015, but may be held liable for subsequent tortious interference. On December 18, 2018, the court denied Apple’s motion regarding patent exhaustion as moot in light of the dismissal of the claims at issue discussed below. On March 14, 2019, the court granted Apple’s motion for summary judgment against our claims for damages under the Cooperation Agreement. Amounts unpaid (and previously accrued) by us under the Cooperation Agreement were recorded in customer-related liabilities (in other current liabilities) at March 31, 2019 and September 30, 2018 (Note 2). On September 14, 2018, we filed a motion to dismiss Apple’s declaratory judgment claims relating to the nine specific patents identified in its original complaint on the basis that we granted Apple and its contract manufacturers a covenant-not-to-sue on those patents. The judge granted our motion on November 20, 2018, which disposed of a total of 56 claims pled by Apple and its contract manufacturers, including non-infringement, validity, damages and patent exhaustion for each of the nine patents. A jury trial commenced on April 15, 2019, and on April 16, 2019, we entered into settlement agreements with Apple and its contract manufacturers to dismiss all outstanding litigation between the parties (Note 12). On January 23, 2017, an Apple subsidiary in China filed two complaints against us in the Beijing Intellectual Property Court. On March 31, 2017, the court granted an application by Apple Inc. to join the actions as a plaintiff, and Apple amended the complaints. One of the complaints alleges a violation of China’s Anti-Monopoly Law (AML complaint); the other complaint requests a determination of the terms of a patent license between us and Apple (FRAND complaint). The AML complaint alleges that (i) we have abused our dominant position in communication standard-essential patents licensing markets and certain global baseband processor chipset markets by charging and offering royalty terms that were excessively high; (ii) we refused to license certain implementers of standardized technologies, including Apple and baseband processor chipset manufacturers; (iii) we forced Apple to use only our products and services; and (iv) we bundled licenses to standard-essential patents with licenses to non-standard-essential patents and imposed other unreasonable or discriminatory trading terms on Apple in violation of the AML. The AML complaint seeks a decree that we cease the alleged abuse of dominance, as well as damages in the amount of 1 billion Chinese renminbi (approximately $149 million based on the exchange rate on March 31, 2019 ). The FRAND complaint makes allegations similar to the AML complaint and further alleges that we refused to offer licensing terms for our cellular standard-essential patents consistent with our FRAND licensing commitments and failed to provide to Apple certain information about our patents. The FRAND complaint seeks (i) a declaration that the license terms offered to Apple by us for our mobile communication standard-essential patents are not compliant with FRAND; (ii) an order that we cease our actions that allegedly violate our FRAND obligations, including pricing on unfair, unreasonable and excessive terms, refusing to deal, imposing unreasonable trade conditions and failing to provide information on our patents; and (iii) a determination of FRAND-compliant license terms for our Chinese standard-essential patents. Apple also seeks its expenses in each of the cases. On August 3, 2017, we received three additional complaints filed by an Apple subsidiary in China and Apple Inc. against us in the Beijing Intellectual Property Court. The complaints seek declaratory judgments of non-infringement of three of our patents. We filed jurisdictional and other objections to the complaints. On November 30, 2017, Apple and certain of its Chinese subsidiaries filed three patent infringement complaints against us in the Beijing Intellectual Property Court. Apple seeks damages and costs. We have filed jurisdictional objections to the complaints. On February 16, 2017, Apple and one of its Japanese subsidiaries filed four complaints against us in the Tokyo District Court. In three of the complaints, Apple seeks declaratory judgment of non-infringement by Apple of three of our patents. Apple further seeks a declaration that our patent rights with respect to those three patents are exhausted by our SULAs with the contract manufacturers of Apple’s devices as well as our sale of baseband processor chipsets. Apple also seeks an award of fees. On January 30, 2018, April 27, 2018 and July 13, 2018, the court dismissed each of Apple’s three declaratory judgment complaints, finding that Apple lacked standing based on the facts it alleged in those complaints. Apple has appealed all three decisions. On December 12, 2018, February 19, 2019 and March 4, 2019, the Intellectual Property High Court ruled in our favor on each of Apple’s appeals, finding that the Tokyo District Courts were correct in dismissing Apple’s declaratory judgment complaints. The court has yet to rule on whether Apple has standing in the remaining complaint. On May 15, 2017, we learned of the fourth complaint. In that complaint, Apple and one of its Japanese subsidiaries seek damages of 100 million Japanese yen (approximately $1 million based on the exchange rate on March 31, 2019 ) from us, based on allegations that we violated the Japanese Antimonopoly Act and the Japanese Civil Code. In particular, the fourth complaint alleges that (i) we hold a monopoly position in the market for baseband processor chipsets that implement certain cellular standards; (ii) we collect double royalties through our license agreements and the sale of baseband processor chipsets which exhaust certain of our patent rights; (iii) we refused to grant Apple a license on FRAND terms and forced Apple to execute a rebate agreement under unreasonable conditions; (iv) we refused to grant Apple a direct license; and (v) we demanded a license fee based on the market value of the total device. We have filed jurisdictional and other objections to this complaint. On March 2, 2017, we learned that Apple and certain of its European subsidiaries issued a Claim Form against us in the UK High Court of Justice, Chancery Division, Patents Court on January 23, 2017. Apple subsequently filed an Amended Claim Form and Particulars of Claim. Both the Amended Claim Form and the Particulars of Claim allege several European competition law claims, including our refusal to license competing chipmakers, failure to offer Apple a direct license to our standard-essential patents on FRAND terms, demanding excessive royalties for our standard-essential patents, and demanding excessive license fees for the use of our standard-essential patents in connection with baseband processor chipsets purchased from us. Apple also seeks declarations that we are obliged to offer a direct patent license to Apple in respect of standard-essential patents actually practiced on FRAND terms and that using our baseband processor chipsets does not infringe any of our patents because we exhausted our patent rights. Finally, Apple seeks declarations that five of our European (UK) patents are invalid and not essential, and an order that each of those patents be revoked. On April 18, 2017, Apple and one of its Taiwanese subsidiaries filed a complaint against us in the Taiwan Intellectual Property Court alleging that we have abused a dominant market position in licensing wireless standard-essential patents and selling baseband processor chipsets, including improper pricing, refusal to deal, exclusive dealing, tying, imposing unreasonable trade terms and discriminatory treatment. The complaint seeks rulings that we not use the sales price of the terminal device as the royalty base for standard-essential patents; not leverage our cellular standard-essential patents to obtain licenses of our non-standard-essential patents or demand cross-licenses without proper compensation; not refuse, reduce, delay or take any other action to limit the supply of our baseband processor chipsets to non-licensees; that we must license our standard-essential patents on FRAND terms; and that we shall not, based on standard-essential patents, seek injunctions. The complaint also seeks damages of 10 million Taiwan dollars (less than $1 million based on the exchange rate on March 31, 2019 ), among other relief. On April 16, 2019, we entered into settlement agreements with Apple and its contract manufacturers to dismiss all outstanding litigation between the parties (Note 12). QUALCOMM Incorporated v. Apple Inc. : On July 6, 2017, we filed a complaint against Apple in the United States District Court for the Southern District of California asserting claims for damages and injunctive relief for infringement of six of our patents directed to a variety of features found in iPhone models. On July 7, 2017, we filed a complaint against Apple in the United States International Trade Commission (ITC) requesting that the ITC institute an investigation pursuant to Section 337 of the Tariff Act of 1930 based on Apple’s infringement of the same six patents. We sought a limited exclusion order and cease and desist order against importation of iPhone models that do not contain a Qualcomm brand baseband processor chipset. The patents have not been declared as essential to any standards organization and are not subject to commitments to license on FRAND terms. Apple filed an Answer and Counterclaims in the District Court case on September 26, 2017. On November 29, 2017, Apple filed a First Amended Answer and Counterclaims asserting that our Snapdragon processors infringe eight Apple patents. On August 8, 2017, the ITC issued a notice of institution of an investigation. On August 25, 2017, we withdrew allegations as to one patent in both the ITC investigation and the district court case. On April 25, 2018, we withdrew allegations as to two additional patents in the ITC investigation, but not the District Court case, in order to satisfy certain briefing limitations and to narrow the issues for hearing. The ITC investigation evidentiary hearing by the Administrative Law Judge (ALJ) was held June 18-26, 2018. The ALJ’s Initial Determination on the merits was issued on September 28, 2018. The ALJ found that we had established a violation of Section 337 by Apple due to the infringement of one of the three asserted patents. However, the ALJ recommended against an exclusion order on the grounds of public interest. On October 15, 2018, the parties each filed petitions for review of portions of the ALJ’s decision by the full ITC. On December 12, 2018, the ITC announced that it would review the ALJ’s determination of violation on one patent and requested public comments on the potential impact on the public interest if an exclusion order is issued. The ITC denied review of the ALJ’s findings of no violation as to the other two patents. On March 26, 2019, the ITC issued its final determination and found the remaining patent to be invalid. The ITC’s final determination did not take a position on the public interest considerations of any potential exclusion order. On March 2, 2018, the District Court granted our motion to sever, for separate trial, Apple’s counterclaims for patent infringement against us. On February 5, 2019, the District Court granted Apple’s motion for summary judgment of non-infringement as to one of our asserted patents. Trial on the remaining three of our asserted patents began on March 4, 2019 and has concluded. The jury returned a verdict in our favor on all three patents, awarding us over $31 million in damages. Post trial proceedings are ongoing, and as a result, we did not record a gain in the second quarter of fiscal 2019. In parallel, Apple has challenged the validity of four of our patents asserted in the first ITC action and corresponding District Court case via Inter Partes Review (IPR) petitions with the United States Patent and Trademark Office (USPTO) Patent Trial and Appeal Board (PTAB). The PTAB has instituted trials on three of those patents. With respect to Apple’s patent claims against us, trial is scheduled to begin on July 15, 2019. We challenged the validity of all of Apple’s asserted patents with the PTAB. Those petitions are pending. On November 1, 2017, we filed a complaint against Apple in San Diego Superior Court for breach of the Master Software Agreement between the companies. The complaint recounts instances when Apple failed to protect our software as required by the agreement and failed to provide sufficient information to which we are entitled under the agreement in order to understand whether other breaches have occurred. The complaint seeks specific performance of Apple’s obligations to cooperate with an audit of its handling of our software, damages and injunctive relief. Apple filed its answer to the complaint on December 19, 2017. On September 24, 2018, we filed a motion seeking to amend our complaint to add causes of action for additional contract breaches and misappropriation of trade secrets. On October 26, 2018, the court granted our motion. We filed an amended complaint on October 31, 2018 and further amended the complaint on November 15, 2018. On December 17, 2018, Apple filed a demurrer objecting to the sufficiency of the second amended complaint. On February 8, 2019, the court denied Apple’s demurrer. Trial is scheduled to begin on February 7, 2020. On November 29, 2017, we filed three additional complaints against Apple in the United States District Court for the Southern District of California alleging infringement of a total of 16 of our patents. The patents have not been declared as essential to any standards organization and are not subject to commitments to license on FRAND terms. The complaints seek damages and injunctive relief. On January 22, 2018, Apple filed answers and counterclaims in each of these cases seeking declaratory judgments that the asserted patents are invalid and/or not infringed. For the case relating to the November 30, 2017 ITC investigation described below, fact discovery closed on March 13, 2019, and trial is scheduled to begin on October 21, 2019. Apple has filed IPR petitions with the PTAB challenging the validity of four of our patents asserted in the November 30, 2017 ITC action and corresponding District Court action. The PTAB has granted the petition as to one of those patents. For the cases not related to the ITC investigation, Apple has challenged all of the asserted patents in IPR proceedings filed in the PTAB. No decisions have yet been issued by the PTAB. In total, Apple has filed 50 IPRs. The PTAB has initiated proceedings in 36 of the IPRs to date. As a result of the IPR proceedings, on August 29, 2018, the court stayed those two cases pending the outcome of the IPR proceedings. On November 30, 2017, we filed a complaint in the ITC accusing certain Apple products of infringing five of our patents. The patents have not been declared as essential to any standards organization and are not subject to commitments to license on FRAND terms. We seek a limited exclusion order and cease and desist order against importation of iPhone models that do not contain a Qualcomm brand baseband processor chipset. On January 2, 2018, the ITC instituted an investigation. The evidentiary hearing by the Administrative Law Judge (ALJ) took place from September 17-24, 2018 and included three of our patents. On March 26, 2019, the ALJ’s Initial Determination was issued, found a violation as to one patent and recommended a limited exclusion order and cease and desist order against iPhones that do not contain a Qualcomm brand baseband processor chipset. The target date for final determination by the ITC is July 26, 2019. On July 17, 2017, we filed complaints against Apple and certain of its subsidiaries in the Federal Republic of Germany, asserting infringement of one of our patents in the Mannheim District Court and infringement of another patent in the Munich District Court. On October 2, 2017, we filed claim extensions in these actions against Apple and certain of its subsidiaries, asserting infringement of two additional patents in the Mannheim District Court and infringement of five additional patents in the Munich District Court. On May 28, 2018, we filed additional claim extensions in these actions against Apple and certain of its subsidiaries, asserting infringement of three additional patents in the Mannheim District Court and infringement of one additional patent in the Munich District Court. The complaints seek remedies including, among other relief, declaratory relief confirming liability on the merits for damages and injunctive relief. The patents have not been declared as essential to any standards organization and are not subject to commitments to license on FRAND terms. Apple and/or its subsidiaries and, in some cases, also Intel have challenged the validity of the asserted patents in opposition proceedings before the European Patent Office or nullity actions before the Federal Patent Court. On October 11, 2018, the Munich District Court issued a judgment declaring one of the patents asserted on October 2, 2017 as not infringed. We have appealed that judgment. On December 20, 2018, the Munich District Court issued judgments declaring one of the patents asserted on July 17, 2017 as infringed and issued an injunction against the infringing Apple products, which would be effective following the posting of financial guarantees. On January 3, 2019, Qualcomm served the requisite financial guarantees to enforce the injunction in the amount of 1.3 billion Euro (approximately $1.5 billion based on the exchange rate at March 31, 2019 ). Apple and its subsidiaries appealed the judgments and requested a preliminary stay of enforcement pending the appeals. On April 9, 2019, the Munich Court of Appeals stayed the enforcement proceedings. On January 15, 2019, the Mannheim District Court issued a judgment declaring one of the patents asserted on October 2, 2017 as not infringed. On January 31, 2019, the Munich District Court issued judgments declaring two further patents (belonging to the same patent family) asserted on October 2, 2017 as not infringed. We have appealed all of these judgments. On February 25, 2019, the Mannheim District Court ordered a stay of infringement proceedings of another patent asserted on October 2, 2017, pending the decision of the Federal Patent Court on validity. On April 5, 2019, the Opposition Division of the European Patent Office revoked a patent that had been asserted on July 17, 2017 before the Mannheim District Court. We intend to appeal this decision. All other patents remain pending. Dates for the pronouncements of judgment and hearings are scheduled for various dates through September 2019. On September 29, 2017, we filed three complaints against Apple and certain of its subsidiaries in the Beijing (China) Intellectual Property Court, asserting infringement of three of our patents. The complaints seek remedies including injunctive relief and costs. The patents have not been declared as essential to any standards organization and are not subject to commitments to license on FRAND terms. On May 10, 2018 and June 21, 2018, Apple filed invalidation requests with the Chinese Patent Review Board (PRB) for the three asserted patents. The PRB has issued orders upholding the validity of all three patents. On November 13, 2017, we filed three complaints against certain of Apple’s subsidiaries in the Beijing (China) High People’s Court, asserting infringement of three of our patents. The complaints seek remedies including injunctive relief, damages and costs. The patents have not been declared as essential to any standards organization and are not subject to commitments to license on FRAND terms. On December 19, 2017, Apple’s subsidiaries filed invalidation requests with the PRB for the three asserted patents. PRB hearings regarding the validity of the patents were held in April and May 2018. The PRB issued rulings upholding the validity of all three patents. On May 22, 2018, Apple’s subsidiaries filed a second invalidation request with the PRB for one of the three asserted patents. The PRB held a hearing regarding this request on October 19, 2018. The PRB issued rulings on two of the second round invalidity petitions, upholding the validity of one patent based on amended claims and upholding the validity of the second patent again. The PRB has not ruled yet on Apple’s second invalidity challenge to the third patent. On November 30, 2018 and December 5, 2018, Apple appealed all three of the original validity rulings from the PRB to the Beijing IP Court. On November 15, 2017, we filed three complaints against certain of Apple’s subsidiaries in the Fuzhou (China) Intermediate People’s Court, asserting infringement of three of our patents. The complaints seek remedies including injunctive relief and costs. The patents have not been declared as essential to any standards organization and are not subject to commitments to license on FRAND terms. Apple’s subsidiaries filed invalidation requests with the PRB on December 8, 2017 for one of the patents and December 11, 2017 for the other two patents. PRB hearings regarding the validity of the patents were held in April and May 2018. The PRB issued orders upholding the validity of two of the patents subject to Apple’s invalidity challenges. The PRB ruled that the third patent was invalid. We subsequently withdrew the infringement action in Fuzhou with respect to the third patent. We have appealed the adverse PRB ruling to the Beijing IP Court. Infringement hearings were held from August through October 30, 2018. On November 30, 2018, the court granted our motions for preliminary injunctions with respect to two of the patents and enjoined Apple’s subsidiaries from importing, selling and offering to sell the iPhone 6S through X. On January 12, 2018, we filed three additional complaints against Apple and certain of its subsidiaries in the Fuzhou (China) Intermediate People’s Court, asserting infringement of three additional patents. The complaints seek remedies including injunctive relief and costs. The patents have not been declared as essential to any standards organization and are not subject to commitments to license on FRAND terms. Also, on January 12, 2018, we filed three complaints against certain of Apple’s subsidiaries in the Jiangsu (China) High People’s Court, asserting infringement of three of our patents. The complaints seek remedies including injunctive relief, damages and costs. The patents have not been declared as essential to any standards organization and are not subject to commitments to license on FRAND terms. On February 5, 2018, Apple’s subsidiaries filed invalidation requests with the PRB. PRB hearings regarding the validity of the patents were held in June 2018. The PRB issued orders upholding the validity of two of the patents and an order partially upholding the validity of another patent. On February 2, 2018, we filed three complaints against certain of Apple’s subsidiaries in the Qingdao (China) Intermediate People’s Court, asserting infringement of three of our patents. The complaints seek remedies including injunctive relief and costs. The patents have not been declared as essential to any standards organization and are not subject to commitments to license on FRAND terms. On February 26, 2018, Apple’s subsidiaries filed invalidation requests with the PRB. PRB hearings regarding the validity of the patents were held in June 2018. The PRB issued orders upholding the validity of two of the patents and invalidating the third patent. We subsequently withdrew the infringement action in Qingdao with respect to the third patent. We filed an appeal of the adverse PRB ruling, and Apple filed an appeal of the other two. Also, on February 2, 2018, we filed three complaints against certain of Apple’s subsidiaries in the Guangzhou (China) Intermediate People’s Court, asserting infringement of three of our patents. The complaints seek remedies including injunctive relief and costs. The patents have not been declared as essential to any standards organization and are not subject to commitments to license on FRAND terms. On March 14, 2018, Apple’s subsidiaries filed invalidation requests with the PRB. PRB hearings regarding the validity of the patents began in July 2018. The PRB issued orders upholding the validity of two of the patents and an order invalidating the third patent. Infringement hearings for all three of the patents were held in October through December 2018. We filed a motion withdrawing the infringement action pertaining to the patent that was invalidated. We have appealed the adverse PRB decision, and Apple has appealed the other two. On June 14, 2018, we filed three complaints against certain of Apple’s subsidiaries in the Guangdong (China) High People’s Court, asserting infringement of three of our patents. The complaints seek remedies including injunctive relief and costs. The patents have not been declared as essential to any standards organization and are not subject to commitments to license on FRAND terms. On August 13, 2018, Apple’s subsidiaries filed invalidation requests with the PRB. The PRB has held hearings regarding all three of the patents. The PRB issued an order invalidating one of the patents and has not ruled yet regarding Apple’s invalidity challenges of the other two patents. On April 16, 2019, we entered into settlement agreements with Apple and its contract manufacturers to

Segment Information (Notes)

Segment Information (Notes)	6 Months Ended
	Mar. 31, 2019
Segment Reporting [Abstract]
Segment Information	Segment Information We are organized on the basis of products and services and have three reportable segments. We conduct business primarily through our QCT (Qualcomm CDMA Technologies) semiconductor business and our QTL (Qualcomm Technology Licensing) licensing business. QCT develops and supplies integrated circuits and system software based on CDMA, OFDMA and other technologies for use in mobile devices, wireless networks, devices used in the Internet of Things (IoT), broadband gateway equipment, consumer electronic devices and automotive telematics and infotainment systems. QTL grants licenses to use portions of our intellectual property portfolio, which includes certain patent rights essential to and/or useful in the manufacture and sale of certain wireless products. Our QSI (Qualcomm Strategic Initiatives) reportable segment makes strategic investments and includes revenues and related costs associated with development contracts with an equity method investee. We also have nonreportable segments, including Qualcomm Government Technologies or QGOV (formerly Qualcomm Cyber Security Solutions) and other wireless technology and service initiatives. We evaluate the performance of our segments based on earnings (loss) before income taxes (EBT). In fiscal 2018, all of the costs related to pre-commercial research and development of 5G technologies, of which we recorded $115 million and $216 million in the second quarter and first six months of fiscal 2018, respectively, were included in unallocated corporate research and development expenses. Beginning in the first quarter of fiscal 2019, all research and development costs associated with 5G technologies are included in segment results. Additionally, beginning in the first quarter of fiscal 2019, certain research and development costs associated with early research and development that were historically included in our QCT segment are allocated to our QTL segment. The net effect of these changes negatively impacted QTL’s EBT by $119 million and $241 million in the second quarter and first six months of fiscal 2019, respectively. QCT's EBT was positively impacted by $32 million and $44 million in the second quarter and first six months of fiscal 2019, respectively. During the first quarter of fiscal 2019, we combined our Small Cells business, which sells products designed for the implementation of small cells to address the challenge of meeting the increased demand for mobile data, into our QCT segment. Revenues and operating results related to the Small Cells business were included in nonreportable segments through the end of fiscal 2018. Prior period segment information has not been adjusted to conform to the new segment presentation as such adjustments are insignificant. The table below presents revenues, EBT and total assets for reportable segments (in millions): Three Months Ended Six Months Ended March 31, March 25, March 31, March 25, Revenues QCT $ 3,722 $ 3,897 $ 7,461 $ 8,548 QTL 1,122 1,219 2,141 2,485 QSI 98 30 125 60 Reconciling items 40 74 97 162 Total $ 4,982 $ 5,220 $ 9,824 $ 11,255 EBT QCT $ 542 $ 608 $ 1,140 $ 1,563 QTL 674 809 1,264 1,664 QSI 17 40 25 51 Reconciling items (427 ) (1,140 ) (1,063 ) (3,020 ) Total $ 806 $ 317 $ 1,366 $ 258 March 31, September 30, Assets QCT $ 2,948 $ 3,041 QTL 2,405 1,472 QSI 1,393 1,279 Reconciling items 27,277 26,926 Total $ 34,023 $ 32,718 Reconciling items for revenues and EBT in the previous table were as follows (in millions): Three Months Ended Six Months Ended March 31, March 25, March 31, March 25, Revenues Nonreportable segments $ 40 $ 74 $ 97 $ 162 $ 40 $ 74 $ 97 $ 162 EBT Unallocated cost of revenues $ (104 ) $ (111 ) $ (218 ) $ (228 ) Unallocated research and development expenses (190 ) (271 ) (337 ) (551 ) Unallocated selling, general and administrative expenses (84 ) (258 ) (148 ) (420 ) Unallocated other income (expenses) (Note 2) 18 (310 ) (130 ) (1,493 ) Unallocated interest expense (159 ) (179 ) (313 ) (348 ) Unallocated investment and other income, net 109 82 130 206 Nonreportable segments (17 ) (93 ) (47 ) (186 ) $ (427 ) $ (1,140 ) $ (1,063 ) $ (3,020 ) Unallocated acquisition-related expenses were comprised as follows (in millions): Three Months Ended Six Months Ended March 31, March 25, March 31, March 25, Cost of revenues $ 99 $ 102 $ 202 $ 208 Research and development expenses 1 2 2 3 Selling, general and administrative expenses 7 214 14 290

Cost Plan (Notes)

Cost Plan (Notes)	6 Months Ended
	Mar. 31, 2019
Restructuring and Related Activities [Abstract]
Cost Plan	Cost Plan In the second quarter of fiscal 2018, we announced a Cost Plan designed to align our cost structure to our long-term margin targets. As part of this plan, we initiated a series of targeted actions across our businesses with the objective to reduce annual costs by $1 billion , excluding incremental costs resulting from any future acquisition of a business. Actions taken under this plan have been completed and have resulted in us achieving substantially all of this target in fiscal 2019 based on our run rate exiting the second quarter of fiscal 2019, excluding litigation costs that are in excess of the baseline spend. During the six months ended March 31, 2019 , we recorded net restructuring and restructuring-related charges related to our Cost Plan of $204 million in other expenses. This consisted of restructuring-related charges of $156 million , primarily related to asset impairment charges (and included a $45 million net gain from the sale of certain assets related to wireless electric vehicle charging applications and the sale of our mobile health nonreportable segment ), and restructuring charges of $48 million , primarily related to severance and consulting costs. Since inception of the Cost Plan, we have incurred a total of $892 million in net restructuring and restructuring-related charges. The remaining restructuring and restructuring-related charges to be incurred related to the plan are expected to be negligible . The restructuring accrual, a portion of which was included in payroll and other benefits related liabilities with the remainder included in other current liabilities, is expected to be substantially paid within the next 12 months. At March 31, 2019 and September 30, 2018 , the restructuring accrual was $25 million and $83 million , respectively.

Fair Value Measurements (Notes)

Fair Value Measurements (Notes)	6 Months Ended
	Mar. 31, 2019
Fair Value Measurements [Abstract]
Fair Value Measurements	Fair Value Measurements The following table presents our fair value hierarchy for assets and liabilities measured at fair value on a recurring basis at March 31, 2019 (in millions): Level 1 Level 2 Level 3 Total Assets Cash equivalents $ 4,830 $ 3,560 $ — $ 8,390 Marketable securities: Corporate bonds and notes — 51 — 51 Auction rate securities — — 35 35 Equity securities 145 — — 145 Total marketable securities 145 51 35 231 Derivative instruments — 12 — 12 Other investments 398 — 63 461 Total assets measured at fair value $ 5,373 $ 3,623 $ 98 $ 9,094 Liabilities Derivative instruments $ — $ 20 $ — $ 20 Other liabilities 399 — 76 475 Total liabilities measured at fair value $ 399 $ 20 $ 76 $ 495 Activity between Levels of the Fair Value Hierarchy. There were no transfers of marketable securities into or out of Level 3 during the six months ended March 31, 2019 and March 25, 2018 . Other investments and other liabilities included in Level 3 at March 31, 2019 were comprised of debt instruments issued by private companies and contingent consideration related to business combinations, respectively. There were no transfers of debt instruments or contingent consideration amounts into or out of Level 3 during the six months ended March 31, 2019 and March 25, 2018 . Assets Measured and Recorded at Fair Value on a Nonrecurring Basis. During the six months ended March 31, 2019 , certain intangible assets and goodwill were written down to their estimated fair values (Note 8). We also measured certain non-marketable equity securities received as non-cash consideration at fair value on a nonrecurring basis (Note 2). The estimation of fair value required the use of significant unobservable inputs, and as a result, the fair value measurements were classified as Level 3. During the six months ended March 31, 2019 and March 25, 2018 , we did not have any other significant assets or liabilities that were measured at fair value on a nonrecurring basis.

Marketable Securities (Notes)

Marketable Securities (Notes)	6 Months Ended
	Mar. 31, 2019
Marketable Securities [Abstract]
Marketable Securities	Marketable Securities Our marketable securities were comprised as follows (in millions): Current Noncurrent (1) March 31, September 30, March 31, September 30, Available-for-sale debt securities: Corporate bonds and notes $ 51 $ 144 $ — $ — Auction rate securities — — 35 35 Total available-for-sale debt securities 51 144 35 35 Equity securities 144 167 1 — Total marketable securities $ 195 $ 311 $ 36 $ 35 (1) Noncurrent marketable securities were included in other assets. The contractual maturities of available-for-sale debt securities were as follows (in millions): March 31, Years to Maturity Less than one year $ 51 No single maturity date 35 Total $ 86 Debt securities with no single maturity date included auction rate securities. During the three and six months ended March 31, 2019 , there were no realized gains or losses on sales of available-for-sale debt securities, and during the three and six months ended March 25, 2018 , gross realized gains were $11 million . As of March 31, 2019 and September 30, 2018, unrealized gains and losses on available for sale debt securities were negligible. As of September 30, 2018 , available-for-sale securities also included equity securities with a fair value of $167 million , including an unrealized gain of $63 million .

Revision of Prior Period Financ

Revision of Prior Period Financial Statements (Notes)	6 Months Ended
	Mar. 31, 2019
Prior Period Revision Adjustments [Line Items]
Revision of Prior Year Financial Statements	Revision of Prior Period Financial Statements We revised certain prior period financial statements for an immaterial error related to the recognition of certain royalty revenues of our QTL segment (Note 1). A summary of revisions to our previously reported financial statements presented herein for comparative purposes is included below (in millions, except per share data). Revised Consolidated Balance Sheet. As of September 30, 2018 As reported Adjustment As revised Deferred tax assets (non-current) $ 904 $ 32 $ 936 Total assets 32,686 32 32,718 Other current liabilities 6,825 153 6,978 Total current liabilities 11,236 153 11,389 Total liabilities 31,758 153 31,911 Retained earnings 663 (121 ) 542 Total stockholders’ equity 928 (121 ) 807 Total liabilities and stockholders’ equity 32,686 32 32,718 Revised Consolidated Statements of Operations. Three Months Ended March 25, 2018 Six Months Ended March 25, 2018 As reported Adjustment As revised As reported Adjustment As revised Licensing revenues $ 1,325 $ (41 ) $ 1,284 $ 2,690 $ (74 ) $ 2,616 Total revenues 5,261 (41 ) 5,220 11,329 (74 ) 11,255 Operating income 441 (41 ) 400 471 (74 ) 397 Income before income taxes 358 (41 ) 317 332 (74 ) 258 Income tax benefit (expense) 5 8 13 (5,922 ) 11 (5,911 ) Net income (loss) 363 (33 ) 330 (5,590 ) (63 ) (5,653 ) Basic earnings (loss) per share 0.25 (0.03 ) 0.22 (3.78 ) (0.04 ) (3.82 ) Diluted earnings (loss) per share 0.24 (0.02 ) 0.22 (3.78 ) (0.04 ) (3.82 ) Revised Consolidated Statements of Comprehensive Income (Loss). Three Months Ended March 25, 2018 Six Months Ended March 25, 2018 As reported Adjustment As revised As reported Adjustment As revised Net income (loss) $ 363 $ (33 ) $ 330 $ (5,590 ) $ (63 ) $ (5,653 ) Total comprehensive income (loss) 523 (33 ) 490 (5,429 ) (63 ) (5,492 ) Revised Consolidated Statement of Cash Flows. We revised our condensed consolidated statement of cash flows for the six months ended March 25, 2018 for this correction, which had no impact to net cash provided by operating activities in the period. Six Months Ended March 25, 2018 As reported Reclassification adjustment (1) Revision adjustment As revised Operating Activities: Net loss $ (5,590 ) $ — $ (63 ) $ (5,653 ) Income tax provision in excess of (less than) income tax payments 5,477 — (11 ) 5,466 Interest expense in excess of interest payments 207 (207 ) — — Other items, net 46 6 — 52 Other assets 70 (12 ) — 58 Payroll, benefits and other liabilities 1,166 213 74 1,453 Net cash provided by operating activities 2,278 — — 2,278 (1) Certain previously reported amounts have been reclassified to conform to the current year presentation. Revised Segment Information. QTL segment results were revised for this correction (Note 7), which resulted in a decrease in QTL revenues and EBT (earnings before income taxes) of $41 million for the three months ended March 25, 2018 and $74 million for the six months ended March 25, 2018 .

Subsequent Event (Notes)

Subsequent Event (Notes)	6 Months Ended
	Mar. 31, 2019
Subsequent Events [Abstract]
Subsequent Event	Subsequent Event On April 16, 2019, we entered into settlement agreements with Apple and its contract manufacturers to dismiss all outstanding litigation between the parties. We also entered into a six-year global patent license agreement with Apple, effective as of April 1, 2019, which includes an option for Apple to extend for two additional years, and a multi-year chipset supply agreement with Apple. While we continue to assess the accounting impacts of the agreements, we currently expect to record revenues from previously satisfied performance obligations in the third quarter of fiscal 2019 resulting from the settlement, consisting of a payment from Apple and the release of our obligations to pay or refund Apple and the contract manufacturers certain customer-related liabilities. Such event is considered a nonrecognized subsequent event.

Basis of Presentation and Sig_2

Basis of Presentation and Significant Accounting Policies Update (Policies)	6 Months Ended
	Mar. 31, 2019
Basis of Presentation [Abstract]
Fiscal Period, Policy	We operate and report using a 52-53 week fiscal year ending on the last Sunday in September. Each of the three-month and six-month periods ended March 31, 2019 and March 25, 2018 included 13 weeks and 26 weeks , respectively.
Use of Estimates, Policy	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and the disclosure of contingent amounts in our condensed consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.
Earnings Per Share, Policy	Basic earnings (loss) per common share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding during the reporting period. Diluted earnings per share is computed by dividing net income by the combination of dilutive common share equivalents, comprised of shares issuable under our share-based compensation plans and shares subject to accelerated share repurchase agreements, if any, and the weighted-average number of common shares outstanding during the reporting period. Due to the net loss for the six months ended March 25, 2018 , all of the common share equivalents issuable under share-based compensation plans had an anti-dilutive effect and were therefore excluded from the computation of diluted loss per share.
Recent Accounting Pronouncements, Policy	In May 2014, the Financial Accounting Standards Board (FASB) issued new accounting guidance related to revenue recognition (ASC 606), which outlines a comprehensive revenue recognition model and supersedes most current revenue recognition accounting guidance and requires increased disclosures. The new accounting guidance defines a five-step approach that requires a company to recognize revenue as control of goods or services transfers to a customer at an amount that reflects the expected consideration to be received in exchange for those goods or services. We adopted ASC 606 in the first quarter of fiscal 2019 using the modified retrospective transition method only to those contracts that were not completed as of October 1, 2018. We recognized the cumulative effect of initially applying the new revenue accounting guidance as an adjustment to opening retained earnings. Prior period results have not been restated and continue to be reported in accordance with the accounting guidance in effect for those periods (ASC 605). We have implemented new accounting policies, systems, processes and internal controls necessary to support the requirements of ASC 606. Adoption of this new accounting guidance most significantly impacts the timing of sales-based royalty revenues, which are the vast majority of our QTL segment’s revenues. Prior to adoption, we recognized sales-based royalties as revenues in the period in which such royalties were reported by licensees, which was after the conclusion of the quarter in which the licensees’ sales occurred and when all other revenue recognition criteria had been met. Under the new accounting guidance, we estimate and recognize sales-based royalties in the period in which the associated sales occur, subject to certain constraints on our ability to estimate such amounts, resulting in an acceleration of revenue recognition compared to the historical method. Since we do not invoice for sales-based royalties estimated and recognized in any given quarter until after the conclusion of that quarter (which is generally the following quarter when such royalties are reported by licensees), revenues recognized from sales-based royalties results in unbilled receivables (included in accounts receivable, net on the consolidated balance sheet). The adoption of ASC 606 did not otherwise have a material impact. The new accounting guidance also impacts the timing of recognizing certain customer incentives, which are recorded as a reduction to revenues in the period that the related revenues are earned. Prior to adoption, we accounted for certain customer incentive arrangements, including volume-related and other pricing rebates or cost reimbursements for marketing and other activities involving certain of our products and technologies, in part based on the maximum potential liability. Under the new accounting guidance, we estimate the amount of all customer incentives. The following table summarizes the cumulative effects of adopting the new revenue accounting guidance (substantially all of which related to the impact to QTL’s sales-based royalties) on our condensed consolidated balance sheet at October 1, 2018 (in millions): Balance as of September 30, Adjustment Opening Balance as of October 1, Assets Accounts receivable, net $ 2,904 $ 957 $ 3,861 Other current assets 699 1 700 Deferred tax assets 936 (98 ) 838 Other assets 1,970 1 1,971 Liabilities Unearned revenues, current $ 500 $ 6 $ 506 Other current liabilities 6,978 125 7,103 Unearned revenues 1,620 (110 ) 1,510 Stockholders’ equity Retained earnings $ 542 $ 840 $ 1,382 The following tables summarize the impacts of adopting the new revenue accounting guidance on our condensed consolidated balance sheet and statements of operations (in millions): As of March 31, 2019 Balance Sheet As Reported ASC 606 Adjustment ASC 605 Assets Accounts receivable, net $ 3,638 $ (851 ) $ 2,787 Other current assets 631 (9 ) 622 Deferred tax assets 3,832 45 3,877 Liabilities Unearned revenues, current $ 478 $ 304 $ 782 Other current liabilities 6,741 (366 ) 6,375 Unearned revenues 1,330 109 1,439 Stockholders’ equity Retained earnings $ 3,309 $ (861 ) $ 2,448 Three Months Ended March 31, 2019 Six Months Ended March 31, 2019 Statements of Operations As Reported ASC 606 Adjustment ASC 605 As Reported ASC 606 Adjustment ASC 605 Revenues Equipment and services $ 3,753 $ (55 ) $ 3,698 $ 7,506 $ (70 ) $ 7,436 Licensing 1,229 (8 ) 1,221 2,318 43 2,361 Investment and other income, net 28 (1 ) 27 33 1 34 Income tax (expense) benefit (143 ) 10 (133 ) 365 4 369 Net income 663 (54 ) 609 1,731 (22 ) 1,709 Adoption of the new accounting guidance had no impact to net cash provided (used) by operating, financing or investing activities on our condensed consolidated statement of cash flows for the six months ended March 31, 2019 . Financial Assets: In January 2016, the FASB issued new accounting guidance on classifying and measuring financial instruments, which requires that all equity investments, other than equity-method investments, in unconsolidated entities generally be measured at fair value through earnings in the statement of operations. Additionally, it changes the disclosure requirements for financial instruments. We adopted the new accounting guidance in the first quarter of fiscal 2019 using the modified retrospective transition method for investments in marketable securities, which have readily determinable fair values, with the cumulative effect of applying the new accounting guidance recognized as an adjustment to opening retained earnings. Upon adoption, we reclassified $50 million of unrealized gains, net of the associated tax effects, related to our investments in marketable securities from accumulated other comprehensive income to opening retained earnings. We have applied the prospective transition method for investments in non-marketable securities, which are investments in privately held companies that do not have readily determinable fair values and will recognize, through earnings, any unrealized gains that have accumulated in the period in which there is an observable transaction, if any. Hedge Instruments: In August 2017, the FASB issued new accounting guidance that expands and refines hedge accounting for both financial and non-financial risks, aligns the recognition and presentation of the effects of hedging instruments and hedged items in the financial statements, and includes targeted improvements related to the assessment of hedge effectiveness. The new accounting guidance also modifies disclosure requirements for hedging activities. We adopted the new accounting guidance in the first quarter of 2019 using the modified retrospective transition method and recorded a negligible adjustment to opening retained earnings. The new accounting guidance did not have a material impact on our condensed consolidated financial statements. Statement of Cash Flows: In August 2016, the FASB issued new accounting guidance related to the classification of certain cash receipts and cash payments in the statement of cash flows. We adopted the new accounting guidance in the first quarter of fiscal 2019 using the retrospective transition method for each period presented, which did not have a material impact on our condensed consolidated statements of cash flows. In November 2016, the FASB issued new accounting guidance that requires companies to include restricted cash and cash equivalents as a component in total cash and cash equivalents on the statement of cash flows. As a result, the consolidated statement of cash flows no longer reflects transfers between cash and cash equivalents and restricted cash and cash equivalents. We adopted the new accounting guidance in the first quarter of fiscal 2019 using the retrospective transition method, which results in certain amounts in fiscal 2018 being adjusted to conform to the new accounting guidance. This includes restricted cash and cash equivalents held during fiscal 2018 related to funds deposited as collateral for outstanding letters of credit in connection with a then proposed acquisition. Restricted cash and cash equivalents related to the outstanding letters of credit totaled $2.0 billion at the end of the fourth quarter of fiscal 2017 and second quarter of fiscal 2018. There was no impact of this change on the activity presented on the condensed consolidated statement of cash flows for the six months ended March 25, 2018. Income Taxes: In October 2016, the FASB issued new accounting guidance that changes the accounting for the income tax effects of intra-entity transfers of assets other than inventory. Under the new accounting guidance, the selling (transferring) entity is required to recognize a current tax expense or benefit upon transfer of the asset. Similarly, the purchasing (receiving) entity is required to recognize a deferred tax asset or deferred tax liability, as well as the related deferred tax benefit or expense, upon receipt of the asset. We adopted the new accounting guidance in the first quarter of fiscal 2019 using the modified retrospective transition method, with the cumulative effect of applying the new accounting guidance recognized as an adjustment to opening retained earnings of $2.6 billion , primarily as the result of establishing a deferred tax asset on the basis difference of certain intellectual property distributed from one of our foreign subsidiaries to a subsidiary in the United States in fiscal 2018 (Note 3). The ongoing impact of this accounting guidance will be dependent on the facts and circumstances of any transactions within its scope. Recent Accounting Pronouncements Not Yet Adopted. Leases: In February 2016, the FASB issued new accounting guidance related to leases that outlines a comprehensive lease accounting model and supersedes the current lease accounting guidance. The new accounting guidance requires lessees to recognize lease liabilities and corresponding right-of-use assets for all leases with lease terms of greater than 12 months. It also changes the definition of a lease and expands the disclosure requirements of lease arrangements. We will adopt the new accounting guidance in the first quarter of fiscal 2020 and expect to use the modified retrospective approach and to elect certain practical expedients, with the cumulative effect of applying the new accounting guidance recognized as an adjustment to opening retained earnings as of the effective date. We are in the process of determining the effects the adoption will have on our consolidated financial statements. Financial Assets: In June 2016, the FASB issued new accounting guidance that changes the accounting for recognizing impairments of financial assets. Under the new accounting guidance, credit losses for financial assets held at amortized cost will be estimated based on expected losses rather than the current incurred loss impairment model. The new accounting guidance also modifies the impairment model for available-for-sale debt securities. The new accounting guidance generally requires the modified retrospective transition method, with the cumulative effect of applying the new accounting guidance recognized as an adjustment to opening retained earnings in the year of adoption, except for certain financial assets where the prospective transition method is required, such as available-for-sale debt securities for which an other-than-temporary impairment has been recorded. We will adopt the new accounting guidance in the first quarter of fiscal 2021, and the impact of this new accounting guidance will largely depend on the composition and credit quality of our investment portfolio, as well as economic conditions at the time of adoption.
Revenue Recognition, Policy	As a result of the adoption of ASC 606, we revised our revenue recognition policy beginning in fiscal 2019 as follows. We derive revenues principally from sales of integrated circuit products and licensing of our intellectual property. We also generate revenues by performing software hosting, software development and other services and from other product sales. The timing of revenue recognition and the amount of revenue actually recognized in each case depends upon a variety of factors, including the specific terms of each arrangement and the nature of our performance obligations. Revenues from sales of our products are recognized upon transfer of control to the customer, which is generally at the time of shipment. Revenues from providing services are typically recognized over time as our performance obligation is satisfied. Revenues from providing services were less than 5% of total revenues for all periods presented. We grant licenses or otherwise provide rights to use portions of our intellectual property portfolio, which, among other rights, includes certain patent rights essential to and/or useful in the manufacture and sale of certain wireless products. Licensees pay royalties based on their sales of products incorporating or using our licensed intellectual property and may also pay a fixed license fee in one or more installments. Sales-based royalties are generally based upon a percentage of the wholesale (i.e., licensee’s) selling price of complete licensed products, net of certain permissible deductions (including transportation, insurance, packing costs and other items). We broadly provide per unit royalty caps that apply to certain categories of complete wireless devices, namely smartphones, tablets and laptops, which in general, effectively provide for a maximum royalty amount per device. We estimate and recognize sales-based royalties on such licensed products in the period in which the associated sales occur, subject to certain constraints on our ability to estimate such royalties. Our estimates of sales-based royalties are based largely on an assessment of the volume of devices supplied into the market that incorporate or use our licensed intellectual property. We estimate sales-based royalties taking into consideration the mix of such sales on a licensee-by-licensee basis, as well as the licensees’ average wholesale prices of such products, and considers all information (historical, current and forecasted) that is reasonably available to us. Our licensees, however, do not report and pay royalties owed for sales in any given quarter until after the conclusion of that quarter, which is generally the following quarter. As a result of recognizing revenues in the period in which the licensees’ sales occur using estimates, adjustments to revenues are required in subsequent periods to reflect changes in estimates as new information becomes available, primarily resulting from actual amounts reported by our licensees. License agreements that require payment of license fees contain a single performance obligation that represents ongoing access to a portfolio of intellectual property over the license term since such agreements provide the licensee the right to access a portfolio of intellectual property that exists at inception of the license agreement and to updates and new intellectual property that is added to the licensed portfolio during the term of the agreement that are highly interdependent or interrelated. Since we expect to expend efforts to develop and transfer updates to our licensed portfolio on an even basis, license fees are recognized as revenues on a straight-line basis over the estimated period of benefit of the license to the licensee. We account for a contract with a customer/licensee when it is legally enforceable, the parties are committed to perform their respective obligations, the rights of the parties regarding the goods and/or services to be transferred are identified, payment terms are identified, the contract has commercial substance and collectability of substantially all of the consideration is probable. From time to time, companies initiate various strategies to attempt to renegotiate, reduce and/or eliminate their need to pay royalties to us for the use of our intellectual property. Certain licensees have disputed, underreported, underpaid, not reported and/or not paid royalties owed to us under their license agreements with us or reported to us in a manner that is not in compliance with their contractual obligations, and such licensees may continue to do so in the future. In such cases, we estimate and recognize licensing revenues only when we have a contract, as defined in ASC 606, and to the extent it is probable that a significant reversal of cumulative revenues recognized will not occur. We analyze the risk of a significant revenue reversal considering both the likelihood and magnitude of the reversal and, if necessary, constrain the amount of estimated revenues recognized in order to mitigate this risk, which may result in recognizing revenues less than amounts contractually owed to us. We measure revenues based on the amount of consideration we expect to receive in exchange for products or services. We record reductions to revenues for customer incentive arrangements, including volume-related and other pricing rebates and cost reimbursements for marketing and other activities involving certain of our products and technologies, in the period that the related revenues are earned. The charges for such arrangements are recorded as a reduction to accounts receivable, net or as other current liabilities based on whether we have the intent and contractual right of offset. Certain of these charges are considered variable consideration and are included in the transaction price primarily based on estimating the most likely amount expected to be provided to the customer/licensee. Revenues recognized from sales of our products and sales-based royalties are generally included in accounts receivable, net (including unbilled receivables) based on our unconditional right to payment for satisfied or partially satisfied performance obligations. We disaggregate our revenues by segment (Note 7) and type of product and services (as presented on our consolidated statement of operations), as we believe this best depicts how the nature, amount, timing and uncertainty of our revenues and cash flows are affected by economic factors. Substantially all of QCT’s revenues consist of equipment revenues that are recognized at a point in time, and substantially all of QTL’s revenues represent licensing revenues that are recognized over time.
Marketable Securities, Policy	Prior to the adoption of the new accounting guidance in the first quarter of fiscal 2019, investments in marketable equity securities were generally classified as available-for-sale equity investments, with net unrealized gains or losses recorded as a component of accumulated other comprehensive income, net of income taxes. Beginning in fiscal 2019, all gains and losses on investments in marketable equity securities, realized and unrealized, are recognized in investment and other income, net.
Non-Marketable Securities, Policy	Prior to the adoption of the new accounting guidance in the first quarter of fiscal 2019, investments in non-marketable equity securities were recorded at cost less impairment, if any, with any losses resulting from an impairment recognized in investment and other income, net. Beginning in fiscal 2019, investments in non-marketable equity securities are recorded at cost, less impairments (if any), adjusted for observable price changes in orderly transactions for identical or similar securities (if any). All gains and losses on investments in non-marketable equity securities, realized and unrealized, are recognized in investment and other income, net.
Segment Reporting, Policy	We evaluate the performance of our segments based on earnings (loss) before income taxes (EBT). In fiscal 2018, all of the costs related to pre-commercial research and development of 5G technologies, of which we recorded $115 million and $216 million in the second quarter and first six months of fiscal 2018, respectively, were included in unallocated corporate research and development expenses. Beginning in the first quarter of fiscal 2019, all research and development costs associated with 5G technologies are included in segment results. Additionally, beginning in the first quarter of fiscal 2019, certain research and development costs associated with early research and development that were historically included in our QCT segment are allocated to our QTL segment. The net effect of these changes negatively impacted QTL’s EBT by $119 million and $241 million in the second quarter and first six months of fiscal 2019, respectively. QCT's EBT was positively impacted by $32 million and $44 million in the second quarter and first six months of fiscal 2019, respectively. During the first quarter of fiscal 2019, we combined our Small Cells business, which sells products designed for the implementation of small cells to address the challenge of meeting the increased demand for mobile data, into our QCT segment. Revenues and operating results related to the Small Cells business were included in nonreportable segments through the end of fiscal 2018. Prior period segment information has not been adjusted to conform to the new segment presentation as such adjustments are insignificant.

Basis of Presentation and Sig_3

Basis of Presentation and Significant Accounting Policies Update (Tables)	6 Months Ended
	Mar. 31, 2019
Basis of Presentation [Abstract]
Schedule of diluted earnings per share	The following table provides information about the diluted earnings (loss) per share calculation (in millions): Three Months Ended Six Months Ended March 31, March 25, March 31, March 25, Dilutive common share equivalents included in diluted shares 3.8 12.2 7.0 — Shares of common stock equivalents not included because the effect would be anti-dilutive or certain performance conditions were not satisfied at the end of the period 17.2 0.1 14.4 44.9
Share-based compensation expense related to all share-based awards	Total share-based compensation expense, related to all of our share-based awards, was comprised as follows (in millions): Three Months Ended Six Months Ended March 31, March 25, March 31, March 25, Cost of revenues $ 7 $ 10 $ 16 $ 21 Research and development 157 151 315 307 Selling, general and administrative 57 61 121 142 Share-based compensation expense before income taxes 221 222 452 470 Related income tax benefit (30 ) (29 ) (79 ) (77 ) $ 191 $ 193 $ 373 $ 393
Cumulative effects of adopting the new revenue accounting standard	The following table summarizes the cumulative effects of adopting the new revenue accounting guidance (substantially all of which related to the impact to QTL’s sales-based royalties) on our condensed consolidated balance sheet at October 1, 2018 (in millions): Balance as of September 30, Adjustment Opening Balance as of October 1, Assets Accounts receivable, net $ 2,904 $ 957 $ 3,861 Other current assets 699 1 700 Deferred tax assets 936 (98 ) 838 Other assets 1,970 1 1,971 Liabilities Unearned revenues, current $ 500 $ 6 $ 506 Other current liabilities 6,978 125 7,103 Unearned revenues 1,620 (110 ) 1,510 Stockholders’ equity Retained earnings $ 542 $ 840 $ 1,382 The following tables summarize the impacts of adopting the new revenue accounting guidance on our condensed consolidated balance sheet and statements of operations (in millions): As of March 31, 2019 Balance Sheet As Reported ASC 606 Adjustment ASC 605 Assets Accounts receivable, net $ 3,638 $ (851 ) $ 2,787 Other current assets 631 (9 ) 622 Deferred tax assets 3,832 45 3,877 Liabilities Unearned revenues, current $ 478 $ 304 $ 782 Other current liabilities 6,741 (366 ) 6,375 Unearned revenues 1,330 109 1,439 Stockholders’ equity Retained earnings $ 3,309 $ (861 ) $ 2,448 Three Months Ended March 31, 2019 Six Months Ended March 31, 2019 Statements of Operations As Reported ASC 606 Adjustment ASC 605 As Reported ASC 606 Adjustment ASC 605 Revenues Equipment and services $ 3,753 $ (55 ) $ 3,698 $ 7,506 $ (70 ) $ 7,436 Licensing 1,229 (8 ) 1,221 2,318 43 2,361 Investment and other income, net 28 (1 ) 27 33 1 34 Income tax (expense) benefit (143 ) 10 (133 ) 365 4 369 Net income 663 (54 ) 609 1,731 (22 ) 1,709

Composition of Certain Financ_2

Composition of Certain Financial Statement Items (Tables)	6 Months Ended
	Mar. 31, 2019
Balance Sheet Related Disclosures [Abstract]
Accounts Receivable	Accounts Receivable (in millions) March 31, September 30, Trade, net of allowances for doubtful accounts of $47 and $56, respectively $ 2,430 $ 2,667 Unbilled receivables 1,196 201 Other 12 36 $ 3,638 $ 2,904
Inventories	Inventories (in millions) March 31, September 30, Raw materials $ 79 $ 72 Work-in-process 820 715 Finished goods 826 906 $ 1,725 $ 1,693
Equity Method and Non-Marketable Equity Investments	The carrying values of our equity method and non-marketable equity investments are recorded in other noncurrent assets and were as follows (in millions): March 31, September 30, Equity method investments $ 354 $ 402 Non-marketable equity investments 779 650 $ 1,133 $ 1,052
Other Current Liabilities	Other Current Liabilities (in millions) March 31, September 30, Customer incentives and other customer-related liabilities $ 3,417 $ 3,500 Accrual for EC fine (Note 6) 1,137 1,167 Income taxes payable 428 453 RF360 Holdings put and call option 1,145 1,137 Other 614 721 $ 6,741 $ 6,978
Changes in Accumulated Other Comprehensive Income	Changes in the components of accumulated other comprehensive income, net of income taxes, in stockholders’ equity in the six months ended March 31, 2019 were as follows (in millions): Foreign Currency Translation Adjustment Noncredit Other-than-Temporary Impairment Losses and Subsequent Changes in Fair Value for Certain Available-for-Sale Debt Securities Net Unrealized Gain (Loss) on Other Available-for-Sale Securities Net Unrealized (Loss) Gain on Derivative Instruments Other Gains Total Accumulated Other Comprehensive Income Balance at September 30, 2018 $ 11 $ 23 $ 243 $ (13 ) $ 1 $ 265 Other comprehensive (loss) income before reclassifications (41 ) — (6 ) 16 (8 ) (39 ) Reclassifications from accumulated other comprehensive income 1 — (51 ) (3 ) — (53 ) Other comprehensive (loss) income (40 ) — (57 ) 13 (8 ) (92 ) Balance at March 31, 2019 $ (29 ) $ 23 $ 186 $ — $ (7 ) $ 173
Investment and Other Income, Net	Investment and Other Income, Net (in millions) Three Months Ended Six Months Ended March 31, March 25, March 31, March 25, Interest and dividend income $ 80 $ 154 $ 155 $ 280 Net gains (losses) on marketable securities 40 3 (33 ) 13 Net gains on other investments 6 47 42 60 Impairment losses on marketable securities and other investments (60 ) (11 ) (69 ) (20 ) Net (losses) gains on derivative investments (1 ) 10 (9 ) 9 Equity in net losses of investees (36 ) (17 ) (58 ) (38 ) Net (losses) gains on foreign currency transactions (1 ) (90 ) 5 (93 ) $ 28 $ 96 $ 33 $ 211

Debt (Tables)

Debt (Tables)	6 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Schedule of long-term debt	The following table provides a summary of our long-term debt (in millions, except percentages): March 31, 2019 September 30, 2018 Amount Effective Rate Amount Effective Rate May 2015 Notes Floating-rate three-month LIBOR plus 0.55% notes due May 20, 2020 $ 250 3.25% $ 250 2.93% Fixed-rate 2.25% notes due May 20, 2020 1,750 3.09% 1,750 3.13% Fixed-rate 3.00% notes due May 20, 2022 2,000 3.51% 2,000 3.73% Fixed-rate 3.45% notes due May 20, 2025 2,000 3.46% 2,000 3.46% Fixed-rate 4.65% notes due May 20, 2035 1,000 4.73% 1,000 4.73% Fixed-rate 4.80% notes due May 20, 2045 1,500 4.72% 1,500 4.72% May 2017 Notes Floating-rate three-month LIBOR plus 0.73% notes due January 30, 2023 500 3.55% 500 3.14% Fixed-rate 2.60% notes due January 30, 2023 1,500 2.70% 1,500 2.70% Fixed-rate 2.90% notes due May 20, 2024 1,500 3.01% 1,500 3.01% Fixed-rate 3.25% notes due May 20, 2027 2,000 3.46% 2,000 3.46% Fixed-rate 4.30% notes due May 20, 2047 1,500 4.47% 1,500 4.47% Total principal 15,500 15,500 Unamortized discount, including debt issuance costs (79 ) (85 ) Hedge accounting fair value adjustments (16 ) (50 ) Total long-term debt $ 15,405 $ 15,365 Reported as: Short-term debt $ — $ — Long-term debt 15,405 15,365 Total $ 15,405 $ 15,365

Commitments and Contingencies_2

Commitments and Contingencies (Tables)	6 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Schedule of obligations under purchase agreements and future minimums lease payments under operating leases	Obligations under our purchase agreements, which primarily relate to integrated circuit product inventory obligations, and future minimum lease payments under our operating leases at March 31, 2019 were as follows (in millions): Purchase Obligations Operating Leases Remainder of fiscal 2019 $ 2,948 $ 74 2020 637 112 2021 326 84 2022 92 54 2023 52 25 Thereafter 17 38 Total $ 4,072 $ 387
Schedule of future minimum lease payments for operating leases	Obligations under our purchase agreements, which primarily relate to integrated circuit product inventory obligations, and future minimum lease payments under our operating leases at March 31, 2019 were as follows (in millions): Purchase Obligations Operating Leases Remainder of fiscal 2019 $ 2,948 $ 74 2020 637 112 2021 326 84 2022 92 54 2023 52 25 Thereafter 17 38 Total $ 4,072 $ 387

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Mar. 31, 2019
Segment Reporting [Abstract]
Revenues, EBT and total assets for reportable segments	The table below presents revenues, EBT and total assets for reportable segments (in millions): Three Months Ended Six Months Ended March 31, March 25, March 31, March 25, Revenues QCT $ 3,722 $ 3,897 $ 7,461 $ 8,548 QTL 1,122 1,219 2,141 2,485 QSI 98 30 125 60 Reconciling items 40 74 97 162 Total $ 4,982 $ 5,220 $ 9,824 $ 11,255 EBT QCT $ 542 $ 608 $ 1,140 $ 1,563 QTL 674 809 1,264 1,664 QSI 17 40 25 51 Reconciling items (427 ) (1,140 ) (1,063 ) (3,020 ) Total $ 806 $ 317 $ 1,366 $ 258 March 31, September 30, Assets QCT $ 2,948 $ 3,041 QTL 2,405 1,472 QSI 1,393 1,279 Reconciling items 27,277 26,926 Total $ 34,023 $ 32,718
Reconciling items for reportable segments - revenues	Reconciling items for revenues and EBT in the previous table were as follows (in millions): Three Months Ended Six Months Ended March 31, March 25, March 31, March 25, Revenues Nonreportable segments $ 40 $ 74 $ 97 $ 162 $ 40 $ 74 $ 97 $ 162 EBT Unallocated cost of revenues $ (104 ) $ (111 ) $ (218 ) $ (228 ) Unallocated research and development expenses (190 ) (271 ) (337 ) (551 ) Unallocated selling, general and administrative expenses (84 ) (258 ) (148 ) (420 ) Unallocated other income (expenses) (Note 2) 18 (310 ) (130 ) (1,493 ) Unallocated interest expense (159 ) (179 ) (313 ) (348 ) Unallocated investment and other income, net 109 82 130 206 Nonreportable segments (17 ) (93 ) (47 ) (186 ) $ (427 ) $ (1,140 ) $ (1,063 ) $ (3,020 )
Reconciling items for reportable segments - EBT	Unallocated acquisition-related expenses were comprised as follows (in millions): Three Months Ended Six Months Ended March 31, March 25, March 31, March 25, Cost of revenues $ 99 $ 102 $ 202 $ 208 Research and development expenses 1 2 2 3 Selling, general and administrative expenses 7 214 14 290 Reconciling items for revenues and EBT in the previous table were as follows (in millions): Three Months Ended Six Months Ended March 31, March 25, March 31, March 25, Revenues Nonreportable segments $ 40 $ 74 $ 97 $ 162 $ 40 $ 74 $ 97 $ 162 EBT Unallocated cost of revenues $ (104 ) $ (111 ) $ (218 ) $ (228 ) Unallocated research and development expenses (190 ) (271 ) (337 ) (551 ) Unallocated selling, general and administrative expenses (84 ) (258 ) (148 ) (420 ) Unallocated other income (expenses) (Note 2) 18 (310 ) (130 ) (1,493 ) Unallocated interest expense (159 ) (179 ) (313 ) (348 ) Unallocated investment and other income, net 109 82 130 206 Nonreportable segments (17 ) (93 ) (47 ) (186 ) $ (427 ) $ (1,140 ) $ (1,063 ) $ (3,020 )

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Mar. 31, 2019
Fair Value Measurements [Abstract]
Fair value hierarchy for assets and liabilities measured at fair value on a recurring basis	The following table presents our fair value hierarchy for assets and liabilities measured at fair value on a recurring basis at March 31, 2019 (in millions): Level 1 Level 2 Level 3 Total Assets Cash equivalents $ 4,830 $ 3,560 $ — $ 8,390 Marketable securities: Corporate bonds and notes — 51 — 51 Auction rate securities — — 35 35 Equity securities 145 — — 145 Total marketable securities 145 51 35 231 Derivative instruments — 12 — 12 Other investments 398 — 63 461 Total assets measured at fair value $ 5,373 $ 3,623 $ 98 $ 9,094 Liabilities Derivative instruments $ — $ 20 $ — $ 20 Other liabilities 399 — 76 475 Total liabilities measured at fair value $ 399 $ 20 $ 76 $ 495

Marketable Securities (Tables)

Marketable Securities (Tables)	6 Months Ended
	Mar. 31, 2019
Marketable Securities [Abstract]
Composition of marketable securities	Our marketable securities were comprised as follows (in millions): Current Noncurrent (1) March 31, September 30, March 31, September 30, Available-for-sale debt securities: Corporate bonds and notes $ 51 $ 144 $ — $ — Auction rate securities — — 35 35 Total available-for-sale debt securities 51 144 35 35 Equity securities 144 167 1 — Total marketable securities $ 195 $ 311 $ 36 $ 35 (1) Noncurrent marketable securities were included in other assets.
Contractual maturities of available-for-sale debt securities	The contractual maturities of available-for-sale debt securities were as follows (in millions): March 31, Years to Maturity Less than one year $ 51 No single maturity date 35 Total $ 86

Revision of Prior Period Fina_2

Revision of Prior Period Financial Statements (Tables)	6 Months Ended
	Mar. 31, 2019
Prior Period Revision Adjustments [Line Items]
Revision of Prior Year Financial Statements	Revised Consolidated Balance Sheet. As of September 30, 2018 As reported Adjustment As revised Deferred tax assets (non-current) $ 904 $ 32 $ 936 Total assets 32,686 32 32,718 Other current liabilities 6,825 153 6,978 Total current liabilities 11,236 153 11,389 Total liabilities 31,758 153 31,911 Retained earnings 663 (121 ) 542 Total stockholders’ equity 928 (121 ) 807 Total liabilities and stockholders’ equity 32,686 32 32,718 Revised Consolidated Statements of Operations. Three Months Ended March 25, 2018 Six Months Ended March 25, 2018 As reported Adjustment As revised As reported Adjustment As revised Licensing revenues $ 1,325 $ (41 ) $ 1,284 $ 2,690 $ (74 ) $ 2,616 Total revenues 5,261 (41 ) 5,220 11,329 (74 ) 11,255 Operating income 441 (41 ) 400 471 (74 ) 397 Income before income taxes 358 (41 ) 317 332 (74 ) 258 Income tax benefit (expense) 5 8 13 (5,922 ) 11 (5,911 ) Net income (loss) 363 (33 ) 330 (5,590 ) (63 ) (5,653 ) Basic earnings (loss) per share 0.25 (0.03 ) 0.22 (3.78 ) (0.04 ) (3.82 ) Diluted earnings (loss) per share 0.24 (0.02 ) 0.22 (3.78 ) (0.04 ) (3.82 ) Revised Consolidated Statements of Comprehensive Income (Loss). Three Months Ended March 25, 2018 Six Months Ended March 25, 2018 As reported Adjustment As revised As reported Adjustment As revised Net income (loss) $ 363 $ (33 ) $ 330 $ (5,590 ) $ (63 ) $ (5,653 ) Total comprehensive income (loss) 523 (33 ) 490 (5,429 ) (63 ) (5,492 ) Revised Consolidated Statement of Cash Flows. We revised our condensed consolidated statement of cash flows for the six months ended March 25, 2018 for this correction, which had no impact to net cash provided by operating activities in the period. Six Months Ended March 25, 2018 As reported Reclassification adjustment (1) Revision adjustment As revised Operating Activities: Net loss $ (5,590 ) $ — $ (63 ) $ (5,653 ) Income tax provision in excess of (less than) income tax payments 5,477 — (11 ) 5,466 Interest expense in excess of interest payments 207 (207 ) — — Other items, net 46 6 — 52 Other assets 70 (12 ) — 58 Payroll, benefits and other liabilities 1,166 213 74 1,453 Net cash provided by operating activities 2,278 — — 2,278 (1) Certain previously reported amounts have been reclassified to conform to the current year presentation.

Basis of Presentation and Sig_4

Basis of Presentation and Significant Accounting Policies Update Earnings (Loss) Per Common Share (Details) - shares shares in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2019	Mar. 25, 2018	Mar. 31, 2019	Mar. 25, 2018
Basis of Presentation and Significant Accounting Policies Update [Abstract]
Dilutive common share equivalents included in diluted shares	3.8	12.2	7	0
Shares of common stock equivalents not included because the effect would be anti-dilutive or certain performance conditions were not satisfied at the end of the period	17.2	0.1	14.4	44.9

Basis of Presentation and Sig_5

Basis of Presentation and Significant Accounting Policies Update Share-Based Compensation (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2019	Mar. 25, 2018	Mar. 31, 2019	Mar. 25, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense before income taxes	$ 221	$ 222	$ 452	$ 470
Related income tax benefit	(30)	(29)	(79)	(77)
Share-based compensation expense, net of income taxes	191	193	373	393
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Unrecognized compensation costs related to non-vested restricted stock units	$ 1,400		$ 1,400
Weighted-average period over which unrecognized compensation expense related to nonvested restricted stock units is expected to be recognized			2 years 2 months
RSUs outstanding	30.4		30.4
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock options outstanding	3.1		3.1
Cost of revenues [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense before income taxes	$ 7	10	$ 16	21
Research and development [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense before income taxes	157	151	315	307
Selling, general and administrative [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share-based compensation expense before income taxes	$ 57	$ 61	$ 121	$ 142

Basis of Presentation and Sig_6

Basis of Presentation and Significant Accounting Policies Update Cumulative Effective of Adopting New Revenue Accounting Guidance (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2019	Mar. 25, 2018	Mar. 31, 2019	Mar. 25, 2018	Oct. 01, 2018	Sep. 30, 2018
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Accounts receivable, net	$ 3,638		$ 3,638		$ 3,861	$ 2,904
Other current assets	631		631		700	699
Deferred tax assets	3,832		3,832		838	936
Other assets	2,113		2,113		1,971	1,970
Unearned revenues, current	478		478		506	500
Other current liabilities	6,741		6,741		7,103	6,978
Unearned revenues	1,330		1,330		1,510	1,620
Retained earnings	3,309		3,309		1,382	542
Equipment and services	3,753	$ 3,936	7,506	$ 8,639
Licensing	1,229	1,284	2,318	2,616
Investment and other income, net	28	96	33	211
Income tax (expense) benefit	(143)	13	365	(5,911)
Net income	663	$ 330	1,731	$ (5,653)
Calculated under Revenue Guidance in Effect before Topic 606 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Accounts receivable, net	2,787		2,787			2,904
Other current assets	622		622			699
Deferred tax assets	3,877		3,877			936
Other assets						1,970
Unearned revenues, current	782		782			500
Other current liabilities	6,375		6,375			6,978
Unearned revenues	1,439		1,439			1,620
Retained earnings	2,448		2,448			$ 542
Equipment and services	3,698		7,436
Licensing	1,221		2,361
Investment and other income, net	27		34
Income tax (expense) benefit	(133)		369
Net income	609		1,709
Difference between Revenue Guidance in Effect before and after Topic 606 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Accounts receivable, net	851		851		957
Other current assets	9		9		1
Deferred tax assets	45		45		98
Other assets					1
Unearned revenues, current	304		304		6
Other current liabilities	366		366		125
Unearned revenues	109		109		110
Retained earnings	(861)		(861)		$ 840
Equipment and services	(55)		(70)
Licensing	(8)		43
Investment and other income, net	1		1
Income tax (expense) benefit	10		4
Net income	$ (54)		$ (22)

Basis of Presentation and Sig_7

Basis of Presentation and Significant Accounting Policies Update Recently Adopted Accounting Pronouncements (Details) - USD ($) $ in Millions	Oct. 01, 2018	Mar. 31, 2019	Sep. 30, 2018	Mar. 25, 2018	Sep. 24, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Retained Earnings	$ 1,382	$ 3,309	$ 542
Restricted cash and cash equivalents		$ 0		$ 2,000
Accounting Standards Update 2016-01 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Retained Earnings	50
Reclassifications from accumulated other comprehensive income	50
Accounting Standards Update 2016-16 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Retained Earnings	$ 2,600
Other Noncurrent Assets [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Restricted cash and cash equivalents				$ 2,000	$ 2,000

Basis of Presentation and Sig_8

Basis of Presentation and Significant Accounting Policies Update Accounting Policy Update (Details) $ in Millions	3 Months Ended	6 Months Ended
	Mar. 31, 2019USD ($)	Mar. 31, 2019USD ($)
Revenue, Performance Obligation [Line Items]
Revenues recognized from performance obligations satisfied in previous periods	$ 398	$ 394
Revenue recognized in period from unearned revenues in prior period		258
Remaining performance obligation amount	1,800	1,800
Revenue, Performance Obligation [Axis]: 2019-04-01
Revenue, Performance Obligation [Line Items]
Remaining performance obligation amount	235	235
Revenue, Performance Obligation [Axis]: 2019-09-30
Revenue, Performance Obligation [Line Items]
Remaining performance obligation amount	470	470
Revenue, Performance Obligation [Axis]: 2020-09-28
Revenue, Performance Obligation [Line Items]
Remaining performance obligation amount	423	423
Revenue, Performance Obligation [Axis]: 2021-09-27
Revenue, Performance Obligation [Line Items]
Remaining performance obligation amount	416	416
Revenue, Performance Obligation [Axis]: 2022-09-26
Revenue, Performance Obligation [Line Items]
Remaining performance obligation amount	193	193
Revenue, Performance Obligation [Axis]: 2023-09-25
Revenue, Performance Obligation [Line Items]
Remaining performance obligation amount	$ 77	$ 77

Composition of Certain Financ_3

Composition of Certain Financial Statement Items Accounts Receivable (Details) - USD ($) $ in Millions	Mar. 31, 2019	Oct. 01, 2018	Sep. 30, 2018
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	$ 2,430		$ 2,667
Unbilled receivables	1,196		201
Other	12		36
Accounts receivables, net	3,638	$ 3,861	2,904
Allowance for doubtful accounts	47		56
Apple [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	$ 960		$ 960

Composition of Certain Financ_4

Composition of Certain Financial Statement Items Inventories (Details) - USD ($) $ in Millions	Mar. 31, 2019	Sep. 30, 2018
Inventory, Net [Abstract]
Raw materials	$ 79	$ 72
Work-in-process	820	715
Finished goods	826	906
Total inventories	$ 1,725	$ 1,693

Composition of Certain Financ_5

Composition of Certain Financial Statement Items Equity Method and Non-marketable Equity Investments (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2019	Sep. 30, 2018
Equity Method and Non-marketable Equity Investments [Line Items]
Equity method investments	$ 354	$ 402
Non-marketable equity investments	779	650
Carrying value of equity method and non-marketable equity investments	$ 1,133	$ 1,052
Equity Method Investee [Member]
Equity Method and Non-marketable Equity Investments [Line Items]
Non-cash consideration received from equity method investee	98
Other Restructuring [Member]
Equity Method and Non-marketable Equity Investments [Line Items]
Non-cash consideration received for divestiture	$ 53

Composition of Certain Financ_6

Composition of Certain Financial Statement Items Other Current Liabilities (Details) - USD ($) $ in Millions	3 Months Ended
	Sep. 29, 2019	Mar. 31, 2019	Oct. 01, 2018	Sep. 30, 2018
Other Current Liabilities [Line Items]
Customer incentives and other customer-related liabilities		$ 3,417		$ 3,500
Income taxes payable		428		453
Other		614		721
Total other current liabilities		6,741	$ 7,103	6,978
EC [Member]
Other Current Liabilities [Line Items]
Accrual for EC fine (Note 6)		1,140		1,167
RF360 Holdings [Member]
Other Current Liabilities [Line Items]
RF360 Holdings put and call option		$ 1,145		$ 1,137
Scenario, Forecast [Member] | RF360 Holdings [Member]
Other Current Liabilities [Line Items]
Agreed exercise price of option to purchase/sell ownership interest	$ 1,150

Composition of Certain Financ_7

Composition of Certain Financial Statement Items Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	Oct. 01, 2018	Mar. 31, 2019
Accumulated Other Comprehensive Income [Roll Forward]
Balance at beginning of period	$ 265	$ 265
Balance at end of period		173
Foreign Currency Translation Adjustment [Member]
Accumulated Other Comprehensive Income [Roll Forward]
Balance at beginning of period	11	11
Other comprehensive (loss) income before reclassifications		(41)
Reclassifications from accumulated other comprehensive income		1
Other comprehensive (loss) income		(40)
Balance at end of period		(29)
Noncredit Other-than-Temporary Impairment Losses and Subsequent Changes in Fair Value for Certain Available-for-Sale Debt Securities [Member]
Accumulated Other Comprehensive Income [Roll Forward]
Balance at beginning of period	23	23
Other comprehensive (loss) income before reclassifications		0
Reclassifications from accumulated other comprehensive income		0
Other comprehensive (loss) income		0
Balance at end of period		23
Net Unrealized Gain (Loss) on Other Available-for-Sale Securities [Member]
Accumulated Other Comprehensive Income [Roll Forward]
Balance at beginning of period	243	243
Other comprehensive (loss) income before reclassifications		(6)
Reclassifications from accumulated other comprehensive income		(51)
Other comprehensive (loss) income		(57)
Balance at end of period		186
Net Unrealized (Loss) Gain on Derivative Instruments [Member]
Accumulated Other Comprehensive Income [Roll Forward]
Balance at beginning of period	(13)	(13)
Other comprehensive (loss) income before reclassifications		16
Reclassifications from accumulated other comprehensive income		(3)
Other comprehensive (loss) income		13
Balance at end of period		0
Other Gains [Member]
Accumulated Other Comprehensive Income [Roll Forward]
Balance at beginning of period	1	1
Other comprehensive (loss) income before reclassifications		(8)
Reclassifications from accumulated other comprehensive income		0
Other comprehensive (loss) income		(8)
Balance at end of period		(7)
Total Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income [Roll Forward]
Balance at beginning of period	265	265
Other comprehensive (loss) income before reclassifications		(39)
Reclassifications from accumulated other comprehensive income		(53)
Other comprehensive (loss) income		(92)
Balance at end of period		$ 173
Reclassification out of Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income [Roll Forward]
Reclassifications from accumulated other comprehensive income	$ 51

Composition of Certain Financ_8

Composition of Certain Financial Statement Items Other Income, Costs and Expenses (Details) - USD ($) $ in Millions	3 Months Ended			6 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 25, 2018	Dec. 24, 2017	Mar. 31, 2019	Mar. 25, 2018	Sep. 27, 2009
Restructuring and restructuring-related charges	$ 25	$ 310		$ 204
Gain (Loss) Related to Litigation Settlement				31
KFTC Complaint [Member]
(Gain) Loss contingency, loss in period						$ (230)
EC [Member]
(Gain) Loss contingency, loss in period			$ (1,200)		$ (1,200)
Other Expenses [Member] | KFTC Complaint [Member]
(Gain) Loss contingency, loss in period	$ 43			$ 43

Composition of Certain Financ_9

Composition of Certain Financial Statement Items Investment and Other Income, Net (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2019	Mar. 25, 2018	Mar. 31, 2019	Mar. 25, 2018
Investment Income, Net [Abstract]
Interest and dividend income	$ 80	$ 154	$ 155	$ 280
Net gains (losses) on marketable securities	40	3	(33)	13
Net gains on other investments	6	47	42	60
Impairment losses on marketable securities and other investments	(60)	(11)	(69)	(20)
Net (losses) gains on derivative investments	(1)	10	(9)	9
Equity in net losses of investees	(36)	(17)	(58)	(38)
Net (losses) gains on foreign currency transactions	(1)	(90)	5	(93)
Investment and other income, net	$ 28	$ 96	$ 33	$ 211

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended			6 Months Ended		12 Months Ended
	Mar. 31, 2019	Dec. 30, 2018	Mar. 25, 2018	Mar. 31, 2019	Mar. 25, 2018	Sep. 29, 2019	Sep. 30, 2018	Oct. 01, 2018
Income Taxes [Line Items]
Income tax benefit	$ (143)		$ 13	$ 365	$ (5,911)
Retained earnings	$ 3,309			3,309			$ 542	$ 1,382
Effective income tax rate (benefit)	18.00%
Unrecognized tax benefits	$ 228			$ 228			$ 217
Scenario, Forecast [Member]
Income Taxes [Line Items]
Effective income tax rate (benefit)						(6.00%)
U.S. Tax Cuts and Jobs Act Effective 2018 [Member]
Income Taxes [Line Items]
Federal statutory income tax rate	21.00%						25.00%
Income tax benefit		$ 570
Accounting Standards Update 2016-16 [Member]
Income Taxes [Line Items]
Retained earnings								$ 2,600

Capital Stock Share Repurchase

Capital Stock Share Repurchase Program (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended	6 Months Ended
	Sep. 30, 2018	Mar. 31, 2019	Mar. 25, 2018	Jul. 26, 2018
Equity, Class of Treasury Stock [Line Items]
Authorized amount				$ 30,000
Payments for stock repurchases		$ 1,019	$ 425
Stock repurchases and retired during the period, shares		16.8	6.8
Stock repurchased and retired during period, value		$ 1,000	$ 425
Stock repurchase program, accounting treatment		To reflect share repurchases in the consolidated balance sheet, we (i) reduce common stock for the par value of the shares, (ii) reduce paid-in capital for the amount in excess of par to zero during the quarter in which the shares are repurchased and (iii) record the residual amount to retained earnings, if any
Accelerated Share Repurchase Program [Member]
Equity, Class of Treasury Stock [Line Items]
Payments for stock repurchases	$ 16,000
Stock repurchases and retired during the period, shares	178.4
$30B stock repurchase program announced July 26, 2018 [Member]
Equity, Class of Treasury Stock [Line Items]
Remaining authorized amount		$ 7,800

Credit Facilities (Details)

Credit Facilities (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Mar. 31, 2019	Sep. 30, 2018
Revolving Credit Facility [Member]
Line of Credit Facility [Abstract]
Credit Facility, Maximum Borrowing Capacity	$ 5,000
Line of Credit Facility, Interest Rate Description	Loans under the Revolving Credit Facility will bear interest, at our option, at either the reserve-adjusted Eurocurrency Rate (determined in accordance with the Revolving Credit Facility) or the Base Rate (determined in accordance with the Revolving Credit Facility), in each case plus an applicable margin based on our long-term unsecured senior, non-credit enhanced debt ratings. The margins over the reserve-adjusted Eurocurrency Rate and the Base Rate will be 0.805% and 0.00% per annum, respectively.
Debt Instrument, Ticking Fee	The Revolving Credit Facility has a facility fee, which accrues at a rate of 0.07% per annum.
Line of Credit Facility, Covenant Terms	maintain a ratio of consolidated earnings before interest, taxes, depreciation and amortization to consolidated interest expense, as defined in each of the respective agreements, of not less than three to one at the end of each fiscal quarter
Line of Credit Facility, Covenant Compliance	we were in compliance with the applicable covenants
Revolving Credit Facility [Member] | February 2020 [Member]
Line of Credit Facility [Abstract]
Credit Facility, Maximum Borrowing Capacity	$ 530
Credit Facility, Expiration Date	Feb. 18, 2020
Revolving Credit Facility [Member] | November 2021 [Member]
Line of Credit Facility [Abstract]
Credit Facility, Maximum Borrowing Capacity	$ 4,470
Credit Facility, Expiration Date	Nov. 8, 2021
Commercial Paper [Member]
Line of Credit Facility [Abstract]
Credit Facility, Maximum Borrowing Capacity	$ 5,000
Outstanding Commercial Paper Classified as Short-term debt	$ 1,000	$ 1,000
Commercial Paper, Weighted Average Interest Rate	2.74%	2.35%
Commercial Paper [Member] | Minimum [Member]
Line of Credit Facility [Abstract]
Debt Instrument, Term	1 day
Commercial Paper [Member] | Maximum [Member]
Line of Credit Facility [Abstract]
Debt Instrument, Term	397 days
Commercial Paper [Member] | Weighted Average [Member]
Line of Credit Facility [Abstract]
Commercial Paper, Weighted Average Remaining Term	29 days	16 days

Debt Long-term Debt (Details)

Debt Long-term Debt (Details) - USD ($) $ in Millions	6 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 25, 2018	Sep. 30, 2018
Long-term Debt [Abstract]
Long-term debt, gross	$ 15,500		$ 15,500
Unamortized discount, including debt issuance costs	(79)		(85)
Hedge accounting fair value adjustments	(16)		(50)
Interest paid related to commercial paper and long-term debt, net of cash received from the related interest rate swaps	281	$ 317
Long-term debt, current maturities	0		0
Long-term debt, excluding current maturities	15,405		15,365
Total long-term debt	15,405		15,365
Long-term debt, fair value	15,400		15,100
May 2015 Notes: Floating-rate three-month LIBOR plus 0.55% notes due May 20, 2020 [Member]
Long-term Debt [Abstract]
Long-term debt, principal amount	$ 250		$ 250
Long-term debt, effective interest rate	3.25%		2.93%
Long-term debt, maturity date	May 20, 2020		May 20, 2020
Long-term debt, basis spread on variable rate	0.55%		0.55%
Long-term debt, interest rate terms	Variable per annum rate equal to three-month LIBOR as determined on the interest determination date plus 0.55%.
May 2015 Notes: Fixed-rate 2.25% notes due May 20, 2020 [Member]
Long-term Debt [Abstract]
Long-term debt, principal amount	$ 1,750		$ 1,750
Long-term debt, effective interest rate	3.09%		3.13%
Long-term debt, stated interest rate	2.25%		2.25%
Long-term debt, maturity date	May 20, 2020		May 20, 2020
Percentage of debt hedged by interest rate derivatives	43.00%
May 2015 Notes: Fixed-rate 3.00% notes due May 20, 2022 [Member]
Long-term Debt [Abstract]
Long-term debt, principal amount	$ 2,000		$ 2,000
Long-term debt, effective interest rate	3.51%		3.73%
Long-term debt, stated interest rate	3.00%		3.00%
Long-term debt, maturity date	May 20, 2022		May 20, 2022
Percentage of debt hedged by interest rate derivatives	50.00%
May 2015 Notes: Fixed-rate 3.45% notes due May 20, 2025 [Member]
Long-term Debt [Abstract]
Long-term debt, principal amount	$ 2,000		$ 2,000
Long-term debt, effective interest rate	3.46%		3.46%
Long-term debt, stated interest rate	3.45%		3.45%
Long-term debt, maturity date	May 20, 2025		May 20, 2025
May 2015 Notes: Fixed-rate 4.65% notes due May 20, 2035 [Member]
Long-term Debt [Abstract]
Long-term debt, principal amount	$ 1,000		$ 1,000
Long-term debt, effective interest rate	4.73%		4.73%
Long-term debt, stated interest rate	4.65%		4.65%
Long-term debt, maturity date	May 20, 2035		May 20, 2035
May 2015 Notes: Fixed-rate 4.80% notes due May 20, 2045 [Member]
Long-term Debt [Abstract]
Long-term debt, principal amount	$ 1,500		$ 1,500
Long-term debt, effective interest rate	4.72%		4.72%
Long-term debt, stated interest rate	4.80%		4.80%
Long-term debt, maturity date	May 20, 2045		May 20, 2045
May 2017 Notes: Floating-rate three-month LIBOR plus 0.73% notes due January 30, 2023 [Member]
Long-term Debt [Abstract]
Long-term debt, principal amount	$ 500		$ 500
Long-term debt, effective interest rate	3.55%		3.14%
Long-term debt, maturity date	Jan. 30, 2023		Jan. 30, 2023
Long-term debt, basis spread on variable rate	0.73%		0.73%
Long-term debt, interest rate terms	Variable per annum rate equal to three-month LIBOR as determined on the interest determination date plus 0.73%.
May 2017 Notes: Fixed-rate 2.60% notes due January 30, 2023 [Member]
Long-term Debt [Abstract]
Long-term debt, principal amount	$ 1,500		$ 1,500
Long-term debt, effective interest rate	2.70%		2.70%
Long-term debt, stated interest rate	2.60%		2.60%
Long-term debt, maturity date	Jan. 30, 2023		Jan. 30, 2023
May 2017 Notes: Fixed-rate 2.90% notes due May 20, 2024 [Member]
Long-term Debt [Abstract]
Long-term debt, principal amount	$ 1,500		$ 1,500
Long-term debt, effective interest rate	3.01%		3.01%
Long-term debt, stated interest rate	2.90%		2.90%
Long-term debt, maturity date	May 20, 2024		May 20, 2024
May 2017 Notes: Fixed-rate 3.25% notes due May 20, 2027 [Member]
Long-term Debt [Abstract]
Long-term debt, principal amount	$ 2,000		$ 2,000
Long-term debt, effective interest rate	3.46%		3.46%
Long-term debt, stated interest rate	3.25%		3.25%
Long-term debt, maturity date	May 20, 2027		May 20, 2027
May 2017 Notes: Fixed-rate 4.30% notes due May 20, 2047 [Member]
Long-term Debt [Abstract]
Long-term debt, principal amount	$ 1,500		$ 1,500
Long-term debt, effective interest rate	4.47%		4.47%
Long-term debt, stated interest rate	4.30%		4.30%
Long-term debt, maturity date	May 20, 2047		May 20, 2047
Interest Rate Swap [Member]
Long-term Debt [Abstract]
Gross notional amount of derivatives	$ 1,800

Commitments and Contingencies L

Commitments and Contingencies Legal and Regulatory Proceedings (Details) € in Millions, $ in Millions, ₩ in Billions

Apr. 16, 2019

Mar. 31, 2019USD ($)

Dec. 24, 2017USD ($)

Mar. 31, 2019USD ($)

Mar. 25, 2018USD ($)

Sep. 30, 2018EUR (€)

Sep. 24, 2017USD ($)

Sep. 24, 2017KRW (₩)

Sep. 27, 2009USD ($)

Sep. 27, 2009KRW (₩)

Jan. 03, 2019EUR (€)

Sep. 30, 2018USD ($)

Apple [Member]

Loss Contingencies [Line Items]

Financial guarantees to enforce injunction

$ 1,500

$ 1,500

Apple [Member] | Euro Member Countries, Euro

Loss Contingencies [Line Items]

Financial guarantees to enforce injunction | €

€ 1,300

KFTC Complaint [Member]

Loss Contingencies [Line Items]

Loss contingency, loss in period

$ 230

Proceeds from fine reversal

$ 56

KFTC Complaint [Member] | Korea (South), Won

Loss Contingencies [Line Items]

Loss contingency, loss in period | ₩

₩ 273.2

KFTC Investigation [Member]

Loss Contingencies [Line Items]

Loss contingency, loss in period

$ 927

KFTC Investigation [Member] | Korea (South), Won

Loss Contingencies [Line Items]

Loss contingency, loss in period | ₩

₩ 1,030

EC [Member]

Loss Contingencies [Line Items]

Loss contingency, loss in period

$ 1,200

$ 1,200

Per annum interest rate for financial guarantees

1.50%

1.50%

Accrual for EC fine - other current liabilities

$ 1,140

$ 1,140

$ 1,167

EC [Member] | Euro Member Countries, Euro

Loss Contingencies [Line Items]

Loss contingency, loss in period | €

€ 997

Other Expenses [Member] | KFTC Complaint [Member]

Loss Contingencies [Line Items]

Loss contingency, loss in period

(43)

$ (43)

Investment and Other Income, Net [Member] | KFTC Complaint [Member]

Loss Contingencies [Line Items]

Interest income related to KFTC complaint

$ 13

Subsequent Event [Member] | Apple [Member]

Loss Contingencies [Line Items]

Terms of settlement agreements with Apple

On April 16, 2019, we entered into settlement agreements with Apple and its contract manufacturers to dismiss all outstanding litigation between the parties.

Commitments and Contingencies P

Commitments and Contingencies Purchase Obligations (Details) $ in Millions	Mar. 31, 2019USD ($)
Unrecorded Unconditional Purchase Obligation [Line Items]
Remainder due in current fiscal year - unrecorded obligation	$ 2,948
Due in two years - unrecorded obligations	637
Due in three years - unrecorded obligations	326
Due in four years - unrecorded obligations	92
Due in five years - unrecorded obligations	52
Thereafter - unrecorded obligations	17
Total - unrecorded obligations	$ 4,072

Commitments and Contingencies O

Commitments and Contingencies Operating Leases (Details) $ in Millions	6 Months Ended
	Mar. 31, 2019USD ($)
Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]
Description of lessee leasing arrangements, operating leases	We lease certain of our land, facilities and equipment under noncancelable operating leases, with terms ranging from less than one year to 15 years and with provisions in certain leases for cost-of-living increases.
Remainder due in current fiscal year - operating lease	$ 74
Due in two years - operating leases	112
Due in three years - operating leases	84
Due in four years - operating leases	54
Due in five years - operating leases	25
Thereafter - operating leases	38
Total operating leases payments due	$ 387

Commitments and Contingencies_3

Commitments and Contingencies Other Commitments (Details) $ in Millions	Mar. 31, 2019USD ($)
QSI [Member]
Other Commitments [Line Items]
Other commitments	$ 226
Other commitment, due in second year	32
QCT [Member] | Minimum [Member]
Other Commitments [Line Items]
Other commitments	$ 88

Segment Information (Details)

Segment Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2019	Mar. 25, 2018	Mar. 31, 2019	Mar. 25, 2018	Sep. 30, 2018
Segment Reporting Information [Line Items]
Segment reporting, factors used to identify entity's reportable segments			We are organized on the basis of products and services and have three reportable segments.
Revenues	$ 4,982	$ 5,220	$ 9,824	$ 11,255
EBT	806	317	1,366	258
Total assets	34,023		34,023		$ 32,718
Cost of revenues	(2,179)	(2,239)	(4,367)	(4,902)
Research and development expense	(1,308)	(1,402)	(2,577)	(2,822)
Selling, general and administrative expense	(573)	(869)	(1,100)	(1,641)
Other expenses	18	(310)	(130)	(1,493)
Interest expense	(162)	(179)	(317)	(350)
Investment and other income, net	28	96	33	211
Reconciling Items [Member]
Segment Reporting Information [Line Items]
Revenues	40	74	97	162
EBT	(427)	(1,140)	(1,063)	(3,020)
Total assets	27,277		27,277		26,926
Cost of revenues	(104)	(111)	(218)	(228)
Research and development expense	(190)	(271)	(337)	(551)
Selling, general and administrative expense	(84)	(258)	(148)	(420)
Other expenses	18	(310)	(130)	(1,493)
Interest expense	(159)	(179)	(313)	(348)
Investment and other income, net	109	82	130	206
Reconciling Items [Member] | Cost of revenues [Member]
Segment Reporting Information [Line Items]
Unallocated acquisition-related expenses	99	102	202	208
Reconciling Items [Member] | Research and development expenses [Member]
Segment Reporting Information [Line Items]
Unallocated acquisition-related expenses	1	2	2	3
Reconciling Items [Member] | Selling, general and administrative expenses [Member]
Segment Reporting Information [Line Items]
Unallocated acquisition-related expenses	7	214	$ 14	290
Corporate, Non-Segment [Member] | Reconciling Items [Member]
Segment Reporting Information [Line Items]
Segment reporting, change in measurement methods			In fiscal 2018, all of the costs related to pre-commercial research and development of 5G technologies, of which we recorded $115 million and $216 million in the second quarter and first six months of fiscal 2018, respectively, were included in unallocated corporate research and development expenses. Beginning in the first quarter of fiscal 2019, all research and development costs associated with 5G technologies are included in segment results.
Change of Segment Methodology [Member] | Reconciling Items [Member]
Segment Reporting Information [Line Items]
Research and development expense	115		$ 216
QCT [Member]
Segment Reporting Information [Line Items]
Segment reporting, change in measurement methods			During the first quarter of fiscal 2019, we combined our Small Cells business, which sells products designed for the implementation of small cells to address the challenge of meeting the increased demand for mobile data, into our QCT segment. Revenues and operating results related to the Small Cells business were included in nonreportable segments through the end of fiscal 2018. Prior period segment information has not been adjusted to conform to the new segment presentation as such adjustments are insignificant.
Revenues	3,722	3,897	$ 7,461	8,548
EBT	542	608	1,140	1,563
Total assets	2,948		$ 2,948		3,041
QTL [Member]
Segment Reporting Information [Line Items]
Segment reporting, change in measurement methods			Additionally, beginning in the first quarter of fiscal 2019, certain research and development costs associated with early research and development that were historically included in our QCT segment are allocated to our QTL segment. The net effect of these changes negatively impacted QTL’s EBT by $119 million and $241 million in the second quarter and first six months of fiscal 2019, respectively. QCT's EBT was positively impacted by $32 million and $44 million in the second quarter and first six months of fiscal 2019, respectively.
Revenues	1,122	1,219	$ 2,141	2,485
EBT	674	809	1,264	1,664
Total assets	2,405		2,405		1,472
QSI [Member]
Segment Reporting Information [Line Items]
Revenues	98	30	125	60
EBT	17	40	25	51
Total assets	1,393		1,393		$ 1,279
Other Segments [Member]
Segment Reporting Information [Line Items]
Revenues	40	74	97	162
EBT	(17)	$ (93)	(47)	$ (186)
Impact to QTL Segment EBT due to Segment Methodology Change [Member]
Segment Reporting Information [Line Items]
EBT	(119)		(241)
Impact to QCT Segment EBT due to Segment Methodology Change [Member]
Segment Reporting Information [Line Items]
EBT	$ 32		$ 44

Cost Plan (Details)

Cost Plan (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended	12 Months Ended
	Mar. 31, 2019	Mar. 25, 2018	Mar. 31, 2019	Sep. 29, 2019	Sep. 30, 2018
Restructuring Cost and Reserve [Line Items]
Cost Plan, announcement date	Jan. 16, 2018
Reduction of annual costs			$ 1,000
Restructuring and restructuring-related charges	$ 25	$ 310	204
Restructuring-related charges			156
Net gain on both sale of assets and a business			45
Restructuring charges			48
Restructuring and restructuring-related charges incurred to date	892		892
Restructuring accrual balance	$ 25		$ 25		$ 83
Scenario, Forecast [Member]
Restructuring Cost and Reserve [Line Items]
Cost Plan, completion date				Sep. 29, 2019

Fair Value Measurements Fair Va

Fair Value Measurements Fair Value Hierarchy (Details) - Fair Value, Measurements, Recurring [Member] $ in Millions	Mar. 31, 2019USD ($)
Assets
Cash equivalents	$ 8,390
Marketable securities	231
Derivative instruments	12
Other investments	461
Total assets measured at fair value	9,094
Liabilities
Derivative instruments	20
Other liabilities	475
Total liabilities measured at fair value	495
Level 1 [Member]
Assets
Cash equivalents	4,830
Marketable securities	145
Derivative instruments	0
Other investments	398
Total assets measured at fair value	5,373
Liabilities
Derivative instruments	0
Other liabilities	399
Total liabilities measured at fair value	399
Level 2 [Member]
Assets
Cash equivalents	3,560
Marketable securities	51
Derivative instruments	12
Other investments	0
Total assets measured at fair value	3,623
Liabilities
Derivative instruments	20
Other liabilities	0
Total liabilities measured at fair value	20
Level 3 [Member]
Assets
Cash equivalents	0
Marketable securities	35
Derivative instruments	0
Other investments	63
Total assets measured at fair value	98
Liabilities
Derivative instruments	0
Other liabilities	76
Total liabilities measured at fair value	76
Corporate bonds and notes [Member]
Assets
Marketable securities	51
Corporate bonds and notes [Member] | Level 1 [Member]
Assets
Marketable securities	0
Corporate bonds and notes [Member] | Level 2 [Member]
Assets
Marketable securities	51
Corporate bonds and notes [Member] | Level 3 [Member]
Assets
Marketable securities	0
Auction rate securities [Member]
Assets
Marketable securities	35
Auction rate securities [Member] | Level 1 [Member]
Assets
Marketable securities	0
Auction rate securities [Member] | Level 2 [Member]
Assets
Marketable securities	0
Auction rate securities [Member] | Level 3 [Member]
Assets
Marketable securities	35
Equity securities [Member]
Assets
Marketable securities	145
Equity securities [Member] | Level 1 [Member]
Assets
Marketable securities	145
Equity securities [Member] | Level 2 [Member]
Assets
Marketable securities	0
Equity securities [Member] | Level 3 [Member]
Assets
Marketable securities	$ 0

Marketable Securities (Details)

Marketable Securities (Details) - USD ($) $ in Millions	Mar. 31, 2019	Sep. 30, 2018
Schedule of Marketable Securities [Line Items]
Available-for-sale - current	$ 51	$ 144
Available-for-sale - noncurrent	35	35
Marketable securities - current	195	311
Marketable securities - noncurrent	36	35
Corporate bonds and notes [Member]
Schedule of Marketable Securities [Line Items]
Available-for-sale - current	51	144
Available-for-sale - noncurrent	0	0
Auction rate securities [Member]
Schedule of Marketable Securities [Line Items]
Available-for-sale - current	0	0
Available-for-sale - noncurrent	35	35
Equity securities [Member]
Schedule of Marketable Securities [Line Items]
Marketable securities - current	144	167
Marketable securities - noncurrent	$ 1	$ 0

Marketable Securities Available

Marketable Securities Available-for-sale Securities (Details) - USD ($) $ in Millions	3 Months Ended	6 Months Ended
	Mar. 31, 2019	Mar. 31, 2019	Sep. 30, 2018
Contractual maturities of available-for-sale debt securities [Abstract]
Years to maturity - less than one year	$ 51	$ 51
Years to maturity - no single maturity date	35	35
Available-for-sale debt securities, fair value	86	86
Available-for-sale Securities [Abstract]
Available-for-sale debt securities, gross realized gains	$ 11	$ 11
Available-for-sale securities equity securities, fair value			$ 167
Available-for-sale equity securities, unrealized gains			$ 63

Revision of Prior Period Fina_3

Revision of Prior Period Financial Statements (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		6 Months Ended
	Mar. 31, 2019	Mar. 25, 2018	Mar. 31, 2019	Mar. 25, 2018	Dec. 30, 2018	Oct. 01, 2018	Sep. 30, 2018	Dec. 24, 2017	Sep. 24, 2017
Prior Period Revision Adjustments [Line Items]
Deferred tax assets (non-current)	$ 3,832		$ 3,832			$ 838	$ 936
Total assets	34,023		34,023				32,718
Other current liabilities	6,741		6,741			7,103	6,978
Total current liabilities	10,517		10,517				11,389
Total liabilities	30,157		30,157				31,911
Retained earnings	3,309		3,309			$ 1,382	542
Total stockholders’ equity	3,866	$ 23,735	3,866	$ 23,735	$ 3,617		807	$ 23,872	$ 30,725
Total liabilities and stockholders’ equity	34,023		34,023				32,718
Licensing revenues	1,229	1,284	2,318	2,616
Total revenues	4,982	5,220	9,824	11,255
Operating income	940	400	1,650	397
Income before income taxes	806	317	1,366	258
Income tax benefit (expense)	(143)	13	365	(5,911)
Net income (loss)	$ 663	$ 330	$ 1,731	$ (5,653)
Basic earnings (loss) per share	$ 0.55	$ 0.22	$ 1.43	$ (3.82)
Basic earnings (loss) per share	$ 0.55	$ 0.22	$ 1.42	$ (3.82)
Total comprehensive income (loss)		$ 490		$ (5,492)
Income tax provision in excess of (less than) income tax payments			$ (958)	5,466
Interest expense in excess of interest payments				0
Other items, net			(190)	52
Other assets			25	58
Payroll, benefits and other liabilities			(727)	1,453
Net cash provided by operating activities				2,278
QTL [Member]
Prior Period Revision Adjustments [Line Items]
Total assets	$ 2,405		2,405				1,472
Total revenues	1,122	1,219	2,141	2,485
Income before income taxes	674	809	1,264	1,664
Previously Reported [Member]
Prior Period Revision Adjustments [Line Items]
Deferred tax assets (non-current)							904
Total assets							32,686
Other current liabilities							6,825
Total current liabilities							11,236
Total liabilities							31,758
Retained earnings							663
Total stockholders’ equity							928
Total liabilities and stockholders’ equity							32,686
Licensing revenues		1,325		2,690
Total revenues		5,261		11,329
Operating income		441		471
Income before income taxes		358		332
Income tax benefit (expense)		5		(5,922)
Net income (loss)		$ 363		$ (5,590)
Basic earnings (loss) per share		$ 0.25		$ (3.78)
Basic earnings (loss) per share		$ 0.24		$ (3.78)
Total comprehensive income (loss)		$ 523		$ (5,429)
Income tax provision in excess of (less than) income tax payments				5,477
Interest expense in excess of interest payments				207
Other items, net				46
Other assets				70
Payroll, benefits and other liabilities				1,166
Net cash provided by operating activities				2,278
Reclassification Adjustment [Member]
Prior Period Revision Adjustments [Line Items]
Net income (loss)				0
Income tax provision in excess of (less than) income tax payments				0
Interest expense in excess of interest payments				(207)
Other items, net				6
Other assets				(12)
Payroll, benefits and other liabilities				213
Net cash provided by operating activities				0
Revision Adjustment [Member]
Prior Period Revision Adjustments [Line Items]
Deferred tax assets (non-current)							32
Total assets							32
Other current liabilities							153
Total current liabilities							153
Total liabilities							153
Retained earnings							(121)
Total stockholders’ equity							(121)
Total liabilities and stockholders’ equity							$ 32
Licensing revenues		(41)		(74)
Total revenues		(41)		(74)
Operating income		(41)		(74)
Income before income taxes		(41)		(74)
Income tax benefit (expense)		8		11
Net income (loss)		$ (33)		$ (63)
Basic earnings (loss) per share		$ (0.03)		$ (0.04)
Basic earnings (loss) per share		$ (0.02)		$ (0.04)
Total comprehensive income (loss)		$ (33)		$ (63)
Income tax provision in excess of (less than) income tax payments				(11)
Interest expense in excess of interest payments				0
Other items, net				0
Other assets				0
Payroll, benefits and other liabilities				74
Net cash provided by operating activities				0
Revision Adjustment [Member] | QTL [Member]
Prior Period Revision Adjustments [Line Items]
Total revenues		$ (41)		$ (74)
Income before income taxes	$ (41)		$ (74)

Subsequent Event (Details)

Subsequent Event (Details)	Apr. 16, 2019
Apple [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Terms of settlement agreements with Apple	On April 16, 2019, we entered into settlement agreements with Apple and its contract manufacturers to dismiss all outstanding litigation between the parties.